{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T15:06:20Z","timestamp":1784214380458,"version":"3.55.0"},"reference-count":248,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s12035-026-06040-2","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T14:42:00Z","timestamp":1784212920000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neuroimmune Regulation of NLRP3 Signalling in Parkinson\u2019s Disease"],"prefix":"10.1007","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4540-1073","authenticated-orcid":false,"given":"Emdormi","family":"Rymbai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6225-7029","authenticated-orcid":false,"given":"Dhritiman","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"6040_CR1","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.amjmed.2019.03.001","volume":"132","author":"MT Hayes","year":"2019","unstructured":"Hayes MT (2019) Parkinson\u2019s disease and parkinsonism. Am J Med 132:802\u2013807. https:\/\/doi.org\/10.1016\/j.amjmed.2019.03.001","journal-title":"Am J Med"},{"key":"6040_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe W, Seppi K, Tanner CM et al (2017) Parkinson disease. Nat Rev Dis Primers 3:1\u201321. https:\/\/doi.org\/10.1038\/nrdp.2017.13","journal-title":"Nat Rev Dis Primers"},{"key":"6040_CR3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3233\/jpd-202221","volume":"11","author":"AM Castonguay","year":"2021","unstructured":"Castonguay AM, Gravel C, L\u00e9vesque M (2021) Treating Parkinson\u2019s disease with antibodies: previous studies and future directions. J Parkinsons Dis 11:71\u201392. https:\/\/doi.org\/10.3233\/jpd-202221","journal-title":"J Parkinsons Dis"},{"key":"6040_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/cbf.4014","volume":"42","author":"E Rymbai","year":"2024","unstructured":"Rymbai E, Sugumar D, Chakkittukandiyil A et al (2024) Molecular insights into the potential effects of selective estrogen receptor \u03b2 agonists in Alzheimer\u2019s and Parkinson\u2019s diseases. Cell Biochem Funct 42:1\u201318. https:\/\/doi.org\/10.1002\/cbf.4014","journal-title":"Cell Biochem Funct"},{"key":"6040_CR5","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/s1474-4422(09)70062-6","volume":"8","author":"EC Hirsch","year":"2009","unstructured":"Hirsch EC, Hunot S (2009) Neuroinflammation in Parkinson\u2019s disease: a target for neuroprotection? Lancet Neurol 8:382\u2013397. https:\/\/doi.org\/10.1016\/s1474-4422(09)70062-6","journal-title":"Lancet Neurol"},{"key":"6040_CR6","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.nbd.2009.11.004","volume":"37","author":"MG Tansey","year":"2010","unstructured":"Tansey MG, Goldberg MS (2010) Neuroinflammation in Parkinson\u2019s disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 37:510\u2013518. https:\/\/doi.org\/10.1016\/j.nbd.2009.11.004","journal-title":"Neurobiol Dis"},{"key":"6040_CR7","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/nrneurol.2010.17","volume":"6","author":"VH Perry","year":"2010","unstructured":"Perry VH, Nicoll JAR, Holmes C (2010) Microglia in neurodegenerative disease. Nat Rev Neurol 6:193\u2013201. https:\/\/doi.org\/10.1038\/nrneurol.2010.17","journal-title":"Nat Rev Neurol"},{"key":"6040_CR8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/0304-3940(95)12192-7","volume":"202","author":"D Blum-Degena","year":"1995","unstructured":"Blum-Degena D, M\u00fcller T, Kuhn W et al (1995) Interleukin-1\u03b2 and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer\u2019s and de novo Parkinson\u2019s disease patients. Neurosci Lett 202:17\u201320. https:\/\/doi.org\/10.1016\/0304-3940(95)12192-7","journal-title":"Neurosci Lett"},{"key":"6040_CR9","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1001\/jamaneurol.2016.2742","volume":"73","author":"XY Qin","year":"2016","unstructured":"Qin XY, Zhang SP, Cao C et al (2016) Aberrations in peripheral inflammatory cytokine levels in Parkinson disease: a systematic review and meta-analysis. JAMA Neurol 73:1316\u20131324. https:\/\/doi.org\/10.1001\/jamaneurol.2016.2742","journal-title":"JAMA Neurol"},{"key":"6040_CR10","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1212\/wnl.38.8.1285","volume":"38","author":"PL McGeer","year":"1988","unstructured":"McGeer PL, Itagaki S, Boyes BE, McGeer EG (1988) Reactive microglia are positive for HLA-DR in the: substantia nigra of Parkinson\u2019s and Alzheimer\u2019s disease brains. Neurology 38:1285\u20131291. https:\/\/doi.org\/10.1212\/wnl.38.8.1285","journal-title":"Neurology"},{"key":"6040_CR11","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/s0361-9230(01)00428-2","volume":"54","author":"J Szel\u00e9nyi","year":"2001","unstructured":"Szel\u00e9nyi J (2001) Cytokines and the central nervous system. Brain Res Bull 54:329\u2013338. https:\/\/doi.org\/10.1016\/s0361-9230(01)00428-2","journal-title":"Brain Res Bull"},{"key":"6040_CR12","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/35094583","volume":"2","author":"SM Allan","year":"2001","unstructured":"Allan SM, Rothwell NJ (2001) Cytokines and acute neurodegeneration. Nat Rev Neurosci 2:734\u2013744. https:\/\/doi.org\/10.1038\/35094583","journal-title":"Nat Rev Neurosci"},{"key":"6040_CR13","doi-asserted-by":"publisher","unstructured":"W B (2015) The blood-brain barrier in neuroimmunology: tales of separation and assimilation. Brain Behav Immun 44:1\u20138. https:\/\/doi.org\/10.1016\/j.bbi.2014.08.007","DOI":"10.1016\/j.bbi.2014.08.007"},{"key":"6040_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1742-2094-5-45","volume":"5","author":"MK McCoy","year":"2008","unstructured":"McCoy MK, Tansey MG (2008) TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation 5:45. https:\/\/doi.org\/10.1186\/1742-2094-5-45","journal-title":"J Neuroinflammation"},{"key":"6040_CR15","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/nature07201","volume":"454","author":"R Medzhitov","year":"2008","unstructured":"Medzhitov R (2008) Origin and physiological roles of inflammation. Nature 454:428\u2013435. https:\/\/doi.org\/10.1038\/nature07201","journal-title":"Nature"},{"key":"6040_CR16","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.immuni.2024.03.010","volume":"57","author":"S Castro-Gomez","year":"2024","unstructured":"Castro-Gomez S, Heneka MT (2024) Innate immune activation in neurodegenerative diseases. Immunity 57:790\u2013814. https:\/\/doi.org\/10.1016\/j.immuni.2024.03.010","journal-title":"Immunity"},{"key":"6040_CR17","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.cmet.2020.01.009","volume":"31","author":"M He","year":"2020","unstructured":"He M, Chiang HH, Luo H et al (2020) An acetylation switch of the NLRP3 inflammasome regulates aging-associated chronic inflammation and insulin resistance. Cell Metab 31:580\u2013591. https:\/\/doi.org\/10.1016\/j.cmet.2020.01.009","journal-title":"Cell Metab"},{"key":"6040_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnagi.2022.879021","volume":"14","author":"HM Blevins","year":"2022","unstructured":"Blevins HM, Xu Y, Biby S, Zhang S (2022) The NLRP3 inflammasome pathway: a review of mechanisms and inhibitors for the treatment of inflammatory diseases. Front Aging Neurosci 14:1\u201327. https:\/\/doi.org\/10.3389\/fnagi.2022.879021","journal-title":"Front Aging Neurosci"},{"key":"6040_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biomedicines9111614","volume":"9","author":"AB Raneros","year":"2021","unstructured":"Raneros AB, Bernet CR, Fl\u00f3rez AB, Suarez-Alvarez B (2021) An epigenetic insight into NLRP3 inflammasome activation in inflammation-related processes. Biomedicines 9:1\u201322. https:\/\/doi.org\/10.3390\/biomedicines9111614","journal-title":"Biomedicines"},{"key":"6040_CR20","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/s41392-021-00687-0","volume":"6","author":"D Li","year":"2021","unstructured":"Li D, Wu M (2021) Pattern recognition receptors in health and diseases. Signal Transduct Target Ther 6:291. https:\/\/doi.org\/10.1038\/s41392-021-00687-0","journal-title":"Signal Transduct Target Ther"},{"key":"6040_CR21","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nri3452","volume":"13","author":"E Latz","year":"2013","unstructured":"Latz E, Xiao TS, Stutz A (2013) Activation and regulation of the inflammasomes. Nat Rev Immunol 13:397\u2013411. https:\/\/doi.org\/10.1038\/nri3452","journal-title":"Nat Rev Immunol"},{"key":"6040_CR22","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.cell.2010.01.040","volume":"140","author":"K Schroder","year":"2010","unstructured":"Schroder K, Tschopp J (2010) The inflammasomes. Cell 140:821\u2013832. https:\/\/doi.org\/10.1016\/j.cell.2010.01.040","journal-title":"Cell"},{"key":"6040_CR23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s12026-012-8317-3","volume":"54","author":"G Yeretssian","year":"2012","unstructured":"Yeretssian G (2012) Effector functions of NLRs in the intestine: innate sensing, cell death, and disease. Immunol Res 54:25\u201336. https:\/\/doi.org\/10.1007\/s12026-012-8317-3","journal-title":"Immunol Res"},{"key":"6040_CR24","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/nri1997","volume":"7","author":"S Mariathasan","year":"2007","unstructured":"Mariathasan S, Monack DM (2007) Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation. Nat Rev Immunol 7:31\u201340. https:\/\/doi.org\/10.1038\/nri1997","journal-title":"Nat Rev Immunol"},{"key":"6040_CR25","doi-asserted-by":"publisher","first-page":"e00015","DOI":"10.1128\/mmbr.00015-18","volume":"82","author":"JA Hayward","year":"2018","unstructured":"Hayward JA, Mathur A, Ngo C, Man SM (2018) Cytosolic recognition of microbes and pathogens: inflammasomes in action. Microbiol Mol Biol Rev 82:e00015-18. https:\/\/doi.org\/10.1128\/mmbr.00015-18","journal-title":"Microbiol Mol Biol Rev"},{"key":"6040_CR26","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s43556-024-00179-x","volume":"5","author":"Z Xu","year":"2024","unstructured":"Xu Z, Kombe Kombe AJ, Deng S et al (2024) NLRP inflammasomes in health and disease. Mol Biomed 5:14. https:\/\/doi.org\/10.1186\/s43556-024-00179-x","journal-title":"Mol Biomed"},{"key":"6040_CR27","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S1097-2765(02)00599-3","volume":"10","author":"F Martinon","year":"2002","unstructured":"Martinon F, Burns K, Tschopp J (2002) The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-\u03b2. Mol Cell 10:417\u2013426. https:\/\/doi.org\/10.1016\/S1097-2765(02)00599-3","journal-title":"Mol Cell"},{"key":"6040_CR28","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/ni.1702","volume":"10","author":"T B\u00fcrckst\u00fcmmer","year":"2009","unstructured":"B\u00fcrckst\u00fcmmer T, Baumann C, Bl\u00fcml S et al (2009) An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome. Nat Immunol 10:266\u2013272. https:\/\/doi.org\/10.1038\/ni.1702","journal-title":"Nat Immunol"},{"key":"6040_CR29","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s10753-022-01730-0","volume":"46","author":"B Sharma","year":"2023","unstructured":"Sharma B, Satija G, Madan A et al (2023) Role of NLRP3 inflammasome and its inhibitors as emerging therapeutic drug candidate for Alzheimer\u2019s disease: a review of mechanism of activation, regulation, and inhibition. Inflammation 46:56\u201387. https:\/\/doi.org\/10.1007\/s10753-022-01730-0","journal-title":"Inflammation"},{"key":"6040_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1151185","author":"X Zheng","year":"2023","unstructured":"Zheng X, Wan J, Tan G (2023) The mechanisms of NLRP3 in flammasome\/pyroptosis activation and their role in diabetic retinopathy. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2023.1151185","journal-title":"Front Immunol"},{"key":"6040_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15476278.2023.2177484","volume":"19","author":"J Mulla","year":"2023","unstructured":"Mulla J, Katti R, Scott MJ (2023) The role of gasdermin-D-mediated pryoptosis in organ injury and its therapeutic implications. Organogenesis 19:1\u201314. https:\/\/doi.org\/10.1080\/15476278.2023.2177484","journal-title":"Organogenesis"},{"key":"6040_CR32","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1007\/s11064-017-2185-0","volume":"42","author":"Z Mao","year":"2017","unstructured":"Mao Z, Liu C, Ji S et al (2017) The NLRP3 inflammasome is involved in the pathogenesis of Parkinson\u2019s disease in rats. Neurochem Res 42:1104\u20131115. https:\/\/doi.org\/10.1007\/s11064-017-2185-0","journal-title":"Neurochem Res"},{"key":"6040_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2022.865772","volume":"13","author":"B Tastan","year":"2022","unstructured":"Tastan B, Arioz BI, Genc S (2022) Targeting NLRP3 inflammasome With Nrf2 inducers in central nervous system disorders. Front Immunol 13:1\u201316. https:\/\/doi.org\/10.3389\/fimmu.2022.865772","journal-title":"Front Immunol"},{"key":"6040_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-019-1413-8","volume":"10","author":"Y Yang","year":"2019","unstructured":"Yang Y, Wang H, Kouadir M et al (2019) Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors. Cell Death Dis 10:1\u201311. https:\/\/doi.org\/10.1038\/s41419-019-1413-8","journal-title":"Cell Death Dis"},{"key":"6040_CR35","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/s41423-021-00670-3","volume":"18","author":"S Paik","year":"2021","unstructured":"Paik S, Kim JK, Silwal P et al (2021) An update on the regulatory mechanisms of NLRP3 inflammasome activation. Cell Mol Immunol 18:1141\u20131160. https:\/\/doi.org\/10.1038\/s41423-021-00670-3","journal-title":"Cell Mol Immunol"},{"key":"6040_CR36","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/cmi.2015.95","volume":"13","author":"EK Jo","year":"2016","unstructured":"Jo EK, Kim JK, Shin DM, Sasakawa C (2016) Molecular mechanisms regulating NLRP3 inflammasome activation. Cell Mol Immunol 13:148\u2013159. https:\/\/doi.org\/10.1038\/cmi.2015.95","journal-title":"Cell Mol Immunol"},{"key":"6040_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2021.732933","volume":"12","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Yang W, Li W, Zhao Y (2021) NLRP3 inflammasome: checkpoint connecting innate and adaptive immunity in autoimmune diseases. Front Immunol 12:1\u201318. https:\/\/doi.org\/10.3389\/fimmu.2021.732933","journal-title":"Front Immunol"},{"key":"6040_CR38","doi-asserted-by":"publisher","first-page":"1214289","DOI":"10.3389\/fimmu.2023.1214289","volume":"14","author":"TSB Honda","year":"2023","unstructured":"Honda TSB, Ku J, Anders HJ (2023) Cell type-specific roles of NLRP3, inflammasome-dependent and -independent, in host defense, sterile necroinflammation, tissue repair, and fibrosis. Front Immunol 14:1214289. https:\/\/doi.org\/10.3389\/fimmu.2023.1214289","journal-title":"Front Immunol"},{"key":"6040_CR39","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/s41583-018-0055-7","volume":"19","author":"MT Heneka","year":"2018","unstructured":"Heneka MT, McManus RM, Latz E (2018) Inflammasome signalling in brain function and neurodegenerative disease. Nat Rev Neurosci 19:610\u2013621. https:\/\/doi.org\/10.1038\/s41583-018-0055-7","journal-title":"Nat Rev Neurosci"},{"key":"6040_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13578-024-01256-y","volume":"14","author":"L Zhang","year":"2024","unstructured":"Zhang L, Tang Y, Huang P et al (2024) Role of NLRP3 inflammasome in central nervous system diseases. Cell Biosci 14:1\u201317. https:\/\/doi.org\/10.1186\/s13578-024-01256-y","journal-title":"Cell Biosci"},{"key":"6040_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41531-018-0061-5","volume":"4","author":"KM von Herrmann","year":"2018","unstructured":"von Herrmann KM, Salas LA, Martinez EM et al (2018) NLRP3 expression in mesencephalic neurons and characterization of a rare NLRP3 polymorphism associated with decreased risk of Parkinson\u2019s disease. NPJ Parkinsons Dis 4:1\u20139. https:\/\/doi.org\/10.1038\/s41531-018-0061-5","journal-title":"NPJ Parkinsons Dis"},{"key":"6040_CR42","doi-asserted-by":"publisher","unstructured":"Alfonso-Loeches S, Ure\u00f1a-Peralta JR, Morillo-Bargues MJ, et al (2014) Role of mitochondria ROS generation in ethanol-induced NLRP3 inflammasome activation and cell death in astroglial cells. Front Cell Neurosci 8. https:\/\/doi.org\/10.3389\/fncel.2014.00216","DOI":"10.3389\/fncel.2014.00216"},{"key":"6040_CR43","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1002\/glia.22891","volume":"63","author":"S Johann","year":"2015","unstructured":"Johann S, Heitzer M, Kanagaratnam M et al (2015) NLRP3 inflammasome is expressed by astrocytes in the SOD1 mouse model of ALS and in human sporadic ALS patients. Glia 63:2260\u20132273. https:\/\/doi.org\/10.1002\/glia.22891","journal-title":"Glia"},{"key":"6040_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/nature11729","author":"MT Heneka","year":"2013","unstructured":"Heneka MT, Kummer MP, Stutz A et al (2013) NLRP3 is activated in Alzheimer\u2019s disease and contributes to pathology in APP\/PS1 mice. Nature. https:\/\/doi.org\/10.1038\/nature11729","journal-title":"Nature"},{"key":"6040_CR45","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1007\/s12264-023-01023-y","volume":"39","author":"QQ Han","year":"2023","unstructured":"Han QQ, Le W (2023) NLRP3 inflammasome-mediated neuroinflammation and related mitochondrial impairment in Parkinson\u2019s disease. Neurosci Bull 39:832\u2013844. https:\/\/doi.org\/10.1007\/s12264-023-01023-y","journal-title":"Neurosci Bull"},{"key":"6040_CR46","doi-asserted-by":"publisher","first-page":"995","DOI":"10.3390\/cells13120995","volume":"13","author":"H Cihankaya","year":"2024","unstructured":"Cihankaya H, Bader V, Winklhofer KF et al (2024) Elevated NLRP3 inflammasome activation is associated with motor neuron degeneration in ALS. Cells 13:995. https:\/\/doi.org\/10.3390\/cells13120995","journal-title":"Cells"},{"key":"6040_CR47","doi-asserted-by":"publisher","first-page":"894298","DOI":"10.3389\/fnmol.2022.894298","volume":"15","author":"Y Cui","year":"2022","unstructured":"Cui Y, Yu H, Bu Z et al (2022) Focus on the role of the NLRP3 inflammasome in multiple sclerosis: pathogenesis, diagnosis, and therapeutics. Front Mol Neurosci 15:894298. https:\/\/doi.org\/10.3389\/fnmol.2022.894298","journal-title":"Front Mol Neurosci"},{"key":"6040_CR48","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41423-025-01275-w","volume":"22","author":"W Xu","year":"2025","unstructured":"Xu W, Huang Y, Zhou R (2025) NLRP3 inflammasome in neuroinflammation and central nervous system diseases. Cell Mol Immunol 22:341\u2013355. https:\/\/doi.org\/10.1038\/s41423-025-01275-w","journal-title":"Cell Mol Immunol"},{"key":"6040_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/bpa.13142","volume":"33","author":"RT Vontell","year":"2023","unstructured":"Vontell RT, de Rivero Vaccari JP, Sun X et al (2023) Identification of inflammasome signaling proteins in neurons and microglia in early and intermediate stages of Alzheimer\u2019s disease. Brain Pathol 33:1\u201317. https:\/\/doi.org\/10.1111\/bpa.13142","journal-title":"Brain Pathol"},{"key":"6040_CR50","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1096\/fj.201600256","volume":"31","author":"K Parzych","year":"2017","unstructured":"Parzych K, Zetterqvist AV, Wright WR et al (2017) Differential role of pannexin-1\/ATP\/P2X7 axis in IL-1\u03b2 release by human monocytes. FASEB J 31:2439\u20132445. https:\/\/doi.org\/10.1096\/fj.201600256","journal-title":"FASEB J"},{"key":"6040_CR51","doi-asserted-by":"publisher","first-page":"114385","DOI":"10.1016\/j.bcp.2020.114385","volume":"187","author":"P Pelegrin","year":"2021","unstructured":"Pelegrin P (2021) P2X7 receptor and the NLRP3 inflammasome: partners in crime. Biochem Pharmacol 187:114385. https:\/\/doi.org\/10.1016\/j.bcp.2020.114385","journal-title":"Biochem Pharmacol"},{"key":"6040_CR52","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41467-017-00227-x","volume":"8","author":"T Tang","year":"2017","unstructured":"Tang T, Lang X, Xu C et al (2017) CLICs-dependent chloride efflux is an essential and proximal upstream event for NLRP3 inflammasome activation. Nat Commun 8:202. https:\/\/doi.org\/10.1038\/s41467-017-00227-x","journal-title":"Nat Commun"},{"key":"6040_CR53","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1038\/ncomms2608","volume":"4","author":"Z Zhong","year":"2013","unstructured":"Zhong Z, Zhai Y, Liang S et al (2013) TRPM2 links oxidative stress to NLRP3 inflammasome activation. Nat Commun 4:1611. https:\/\/doi.org\/10.1038\/ncomms2608","journal-title":"Nat Commun"},{"key":"6040_CR54","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/ni.1831","volume":"11","author":"R Zhou","year":"2010","unstructured":"Zhou R, Tardivel A, Thorens B et al (2010) Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 11:136\u2013140. https:\/\/doi.org\/10.1038\/ni.1831","journal-title":"Nat Immunol"},{"key":"6040_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-023-44203-0","volume":"14","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Luo L, Xu X et al (2023) Acetylation is required for full activation of the NLRP3 inflammasome. Nat Commun 14:1\u201312. https:\/\/doi.org\/10.1038\/s41467-023-44203-0","journal-title":"Nat Commun"},{"key":"6040_CR56","doi-asserted-by":"publisher","first-page":"115735","DOI":"10.1016\/j.biopha.2023.115735","volume":"168","author":"Q Huang","year":"2023","unstructured":"Huang Q, Yang P, Liu Y et al (2023) The interplay between \u03b1-synuclein and NLRP3 inflammasome in Parkinson\u2019s disease. Biomed Pharmacother 168:115735. https:\/\/doi.org\/10.1016\/j.biopha.2023.115735","journal-title":"Biomed Pharmacother"},{"key":"6040_CR57","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.3233\/JPD-223290","volume":"12","author":"LTN Nguyen","year":"2022","unstructured":"Nguyen LTN, Nguyen HD, Kim YJ et al (2022) Role of NLRP3 inflammasome in Parkinson\u2019s disease and therapeutic considerations. J Parkinsons Dis 12:2117\u20132133. https:\/\/doi.org\/10.3233\/JPD-223290","journal-title":"J Parkinsons Dis"},{"key":"6040_CR58","doi-asserted-by":"publisher","first-page":"719807","DOI":"10.3389\/fimmu.2021.719807","volume":"12","author":"Y Li","year":"2021","unstructured":"Li Y, Xia Y, Yin S et al (2021) Targeting microglial \u03b1-synuclein\/TLRs\/NF-kappaB\/NLRP3 inflammasome axis in Parkinson\u2019s disease. Front Immunol 12:719807. https:\/\/doi.org\/10.3389\/fimmu.2021.719807","journal-title":"Front Immunol"},{"key":"6040_CR59","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak H, Del TK, R\u00fcb U et al (2003) Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol Aging 24:197\u2013211. https:\/\/doi.org\/10.1016\/S0197-4580(02)00065-9","journal-title":"Neurobiol Aging"},{"key":"6040_CR60","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/ana.24448","volume":"78","author":"E Svensson","year":"2015","unstructured":"Svensson E, Horv\u00e1th-Puh\u00f3 E, Thomsen RW et al (2015) Vagotomy and subsequent risk of Parkinson\u2019s disease. Ann Neurol 78:522\u2013529. https:\/\/doi.org\/10.1002\/ana.24448","journal-title":"Ann Neurol"},{"key":"6040_CR61","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.nbd.2012.09.007","volume":"50","author":"D Devos","year":"2013","unstructured":"Devos D, Lebouvier T, Lardeux B et al (2013) Colonic inflammation in Parkinson\u2019s disease. Neurobiol Dis 50:42\u201348. https:\/\/doi.org\/10.1016\/j.nbd.2012.09.007","journal-title":"Neurobiol Dis"},{"key":"6040_CR62","doi-asserted-by":"publisher","first-page":"eaah4066","DOI":"10.1126\/scitranslmed.aah4066","volume":"10","author":"R Gordon","year":"2018","unstructured":"Gordon R, Albornoz EA, Christie DC et al (2018) Inflammasome inhibition prevents \u03b1-synuclein pathology and dopaminergic neurodegeneration in mice. Sci Transl Med 10:eaah4066. https:\/\/doi.org\/10.1126\/scitranslmed.aah4066","journal-title":"Sci Transl Med"},{"key":"6040_CR63","doi-asserted-by":"publisher","first-page":"e28032","DOI":"10.1371\/journal.pone.0028032","volume":"6","author":"CB Forsyth","year":"2011","unstructured":"Forsyth CB, Shannon KM, Kordower JH et al (2011) Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson\u2019s disease. PLoS ONE 6:e28032. https:\/\/doi.org\/10.1371\/journal.pone.0028032","journal-title":"PLoS ONE"},{"key":"6040_CR64","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1111\/j.1471-4159.2010.06879.x","volume":"114","author":"RF Villar\u00e1n","year":"2010","unstructured":"Villar\u00e1n RF, Espinosa-Oliva AM, Sarmiento M et al (2010) Ulcerative colitis exacerbates lipopolysaccharide-induced damage to the nigral dopaminergic system: potential risk factor in Parkinson`s disease. J Neurochem 114:1687\u20131700. https:\/\/doi.org\/10.1111\/j.1471-4159.2010.06879.x","journal-title":"J Neurochem"},{"key":"6040_CR65","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41418-018-0124-5","volume":"26","author":"E Lee","year":"2019","unstructured":"Lee E, Hwang I, Park S et al (2019) MPTP-driven NLRP3 inflammasome activation in microglia plays a central role in dopaminergic neurodegeneration. Cell Death Differ 26:213\u2013228. https:\/\/doi.org\/10.1038\/s41418-018-0124-5","journal-title":"Cell Death Differ"},{"key":"6040_CR66","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1186\/s12974-023-02989-2","volume":"20","author":"H Zhu","year":"2023","unstructured":"Zhu H, Xiao F, Xiao Y et al (2023) Targeting CB2R in astrocytes for Parkinson\u2019s disease therapy: unraveling the Foxg1-mediated neuroprotective mechanism through autophagy-mediated NLRP3 degradation. J Neuroinflammation 20:304. https:\/\/doi.org\/10.1186\/s12974-023-02989-2","journal-title":"J Neuroinflammation"},{"key":"6040_CR67","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2019.8297","author":"X Wang","year":"2019","unstructured":"Wang X, Chi J, Huang D et al (2019) \u03b1-synuclein promotes progression of Parkinson\u2019s disease by upregulating autophagy signaling pathway to activate NLRP3 inflammasome. Exp Ther Med. https:\/\/doi.org\/10.3892\/etm.2019.8297","journal-title":"Exp Ther Med"},{"key":"6040_CR68","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature21029","volume":"541","author":"SA Liddelow","year":"2017","unstructured":"Liddelow SA, Guttenplan KA, Clarke LE et al (2017) Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541:481\u2013487. https:\/\/doi.org\/10.1038\/nature21029","journal-title":"Nature"},{"key":"6040_CR69","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/s41591-018-0051-5","volume":"24","author":"SP Yun","year":"2018","unstructured":"Yun SP, Kam T-I, Panicker N et al (2018) Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson\u2019s disease. Nat Med 24:931\u2013938. https:\/\/doi.org\/10.1038\/s41591-018-0051-5","journal-title":"Nat Med"},{"key":"6040_CR70","doi-asserted-by":"publisher","first-page":"604","DOI":"10.3390\/biomedicines13030604","volume":"13","author":"HN Choi","year":"2025","unstructured":"Choi HN, Kim S-H, Jo MG et al (2025) A2-astrocyte activation by short-term hypoxia rescues \u03b1-synuclein pre-formed-fibril-induced neuronal cell death. Biomedicines 13:604. https:\/\/doi.org\/10.3390\/biomedicines13030604","journal-title":"Biomedicines"},{"key":"6040_CR71","doi-asserted-by":"publisher","first-page":"113938","DOI":"10.1016\/j.intimp.2024.113938","volume":"146","author":"C-M Qiao","year":"2025","unstructured":"Qiao C-M, Tan L-L, Ma X-Y et al (2025) Mechanism of S100A9-mediated astrocyte activation via TLR4\/NF-\u03baB in Parkinson\u2019s disease. Int Immunopharmacol 146:113938. https:\/\/doi.org\/10.1016\/j.intimp.2024.113938","journal-title":"Int Immunopharmacol"},{"key":"6040_CR72","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.3390\/cells12192336","volume":"12","author":"T Wang","year":"2023","unstructured":"Wang T, Sun Y, Dettmer U (2023) Astrocytes in Parkinson\u2019s disease: from role to possible intervention. Cells 12:2336. https:\/\/doi.org\/10.3390\/cells12192336","journal-title":"Cells"},{"key":"6040_CR73","doi-asserted-by":"publisher","first-page":"883","DOI":"10.3390\/ph16060883","volume":"16","author":"EdlRM Cabrera Ranaldi","year":"2023","unstructured":"Cabrera Ranaldi EdlRM, Nuytemans K, Martinez A et al (2023) Proof-of-principle study of inflammasome signaling proteins as diagnostic biomarkers of the inflammatory response in Parkinson\u2019s disease. Pharmaceuticals (Basel) 16:883. https:\/\/doi.org\/10.3390\/ph16060883","journal-title":"Pharmaceuticals (Basel)"},{"key":"6040_CR74","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41531-020-00147-6","volume":"7","author":"FL Anderson","year":"2021","unstructured":"Anderson FL, von Herrmann KM, Andrew AS et al (2021) Plasma-borne indicators of inflammasome activity in Parkinson\u2019s disease patients. NPJ Parkinsons Dis 7:2. https:\/\/doi.org\/10.1038\/s41531-020-00147-6","journal-title":"NPJ Parkinsons Dis"},{"key":"6040_CR75","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41531-024-00744-9","volume":"10","author":"K Senkevich","year":"2024","unstructured":"Senkevich K, Liu L, Alvarado CX et al (2024) Lack of genetic evidence for NLRP3 inflammasome involvement in Parkinson\u2019s disease pathogenesis. NPJ Parkinsons Dis 10:145. https:\/\/doi.org\/10.1038\/s41531-024-00744-9","journal-title":"NPJ Parkinsons Dis"},{"key":"6040_CR76","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41531-025-00963-8","volume":"11","author":"B Cyr","year":"2025","unstructured":"Cyr B, Vontell RT, Hadad R et al (2025) IC100 blocks inflammasome activation induced by \u03b1-synuclein aggregates and ASC specks. NPJ Parkinsons Dis 11:92. https:\/\/doi.org\/10.1038\/s41531-025-00963-8","journal-title":"NPJ Parkinsons Dis"},{"key":"6040_CR77","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1016\/j.neuron.2022.05.009","volume":"110","author":"N Panicker","year":"2022","unstructured":"Panicker N, Kam T-I, Wang H et al (2022) Neuronal NLRP3 is a parkin substrate that drives neurodegeneration in Parkinson\u2019s disease. Neuron 110:2422-2437.e9. https:\/\/doi.org\/10.1016\/j.neuron.2022.05.009","journal-title":"Neuron"},{"key":"6040_CR78","doi-asserted-by":"publisher","first-page":"108130","DOI":"10.1016\/j.isci.2023.108130","volume":"26","author":"K-J He","year":"2023","unstructured":"He K-J, Zhang J-B, Liu J-Y et al (2023) LRRK2 G2019S promotes astrocytic inflammation induced by oligomeric \u03b1-synuclein through NF-\u03baB pathway. iScience 26:108130. https:\/\/doi.org\/10.1016\/j.isci.2023.108130","journal-title":"iScience"},{"key":"6040_CR79","doi-asserted-by":"publisher","first-page":"104879","DOI":"10.1016\/j.jbc.2023.104879","volume":"299","author":"E Pajarillo","year":"2023","unstructured":"Pajarillo E, Kim S, Digman A et al (2023) The role of microglial LRRK2 kinase in manganese-induced inflammatory neurotoxicity via NLRP3 inflammasome and RAB10-mediated autophagy dysfunction. J Biol Chem 299:104879. https:\/\/doi.org\/10.1016\/j.jbc.2023.104879","journal-title":"J Biol Chem"},{"key":"6040_CR80","doi-asserted-by":"publisher","first-page":"4028","DOI":"10.1038\/ncomms5028","volume":"5","author":"DC Sch\u00f6ndorf","year":"2014","unstructured":"Sch\u00f6ndorf DC, Aureli M, McAllister FE et al (2014) iPSC-derived neurons from GBA1-associated Parkinson\u2019s disease patients show autophagic defects and impaired calcium homeostasis. Nat Commun 5:4028. https:\/\/doi.org\/10.1038\/ncomms5028","journal-title":"Nat Commun"},{"key":"6040_CR81","doi-asserted-by":"publisher","first-page":"3734","DOI":"10.1093\/hmg\/ddq288","volume":"19","author":"I Irrcher","year":"2010","unstructured":"Irrcher I, Aleyasin H, Seifert EL et al (2010) Loss of the Parkinson\u2019s disease-linked gene DJ-1 perturbs mitochondrial dynamics. Hum Mol Genet 19:3734\u20133746. https:\/\/doi.org\/10.1093\/hmg\/ddq288","journal-title":"Hum Mol Genet"},{"key":"6040_CR82","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41531-017-0032-2","volume":"3","author":"S Sarkar","year":"2017","unstructured":"Sarkar S, Malovic E, Harishchandra DS et al (2017) Mitochondrial impairment in microglia amplifies NLRP3 inflammasome proinflammatory signaling in cell culture and animal models of Parkinson\u2019s disease. NPJ Parkinsons Dis 3:30. https:\/\/doi.org\/10.1038\/s41531-017-0032-2","journal-title":"NPJ Parkinsons Dis"},{"key":"6040_CR83","doi-asserted-by":"publisher","first-page":"9611","DOI":"10.1073\/pnas.1112368109","volume":"109","author":"B Dehay","year":"2012","unstructured":"Dehay B, Ramirez A, Martinez-Vicente M et al (2012) Loss of P-type ATPase ATP13A2\/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration. Proc Natl Acad Sci 109:9611\u20139616. https:\/\/doi.org\/10.1073\/pnas.1112368109","journal-title":"Proc Natl Acad Sci"},{"key":"6040_CR84","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nm.3983","volume":"22","author":"W Wang","year":"2016","unstructured":"Wang W, Wang X, Fujioka H et al (2016) Parkinson\u2019s disease\u2013associated mutant VPS35 causes mitochondrial dysfunction by recycling DLP1 complexes. Nat Med 22:54\u201363. https:\/\/doi.org\/10.1038\/nm.3983","journal-title":"Nat Med"},{"key":"6040_CR85","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.cell.2014.11.047","volume":"160","author":"Y Yan","year":"2015","unstructured":"Yan Y, Jiang W, Liu L et al (2015) Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome. Cell 160:62\u201373. https:\/\/doi.org\/10.1016\/j.cell.2014.11.047","journal-title":"Cell"},{"key":"6040_CR86","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1124\/pharmrev.122.000618","volume":"75","author":"B Channer","year":"2023","unstructured":"Channer B, Matt SM, Nickoloff-Bybel EA et al (2023) Dopamine, immunity, and disease. Pharmacol Rev 75:62\u2013158. https:\/\/doi.org\/10.1124\/pharmrev.122.000618","journal-title":"Pharmacol Rev"},{"key":"6040_CR87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejphar.2019.172826","volume":"866","author":"Y Yoshioka","year":"2020","unstructured":"Yoshioka Y, Sugino Y, Shibagaki F et al (2020) Dopamine attenuates lipopolysaccharide-induced expression of proinflammatory cytokines by inhibiting the nuclear translocation of NF-\u03baB p65 through the formation of dopamine quinone in microglia. Eur J Pharmacol 866:1\u201312. https:\/\/doi.org\/10.1016\/j.ejphar.2019.172826","journal-title":"Eur J Pharmacol"},{"key":"6040_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells9071687","volume":"9","author":"M Pajares","year":"2020","unstructured":"Pajares M, I Rojo A, Manda G et al (2020) Inflammation in Parkinson\u2019s disease: mechanisms and therapeutic implications. Cells 9:1\u201332. https:\/\/doi.org\/10.3390\/cells9071687","journal-title":"Cells"},{"key":"6040_CR89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-022-02410-4","volume":"19","author":"AF Pike","year":"2022","unstructured":"Pike AF, Longhena F, Faustini G et al (2022) Dopamine signaling modulates microglial NLRP3 inflammasome activation: implications for Parkinson\u2019s disease. J Neuroinflammation 19:1\u201316. https:\/\/doi.org\/10.1186\/s12974-022-02410-4","journal-title":"J Neuroinflammation"},{"key":"6040_CR90","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jphs.2021.10.004","volume":"148","author":"Y Yoshioka","year":"2022","unstructured":"Yoshioka Y, Sugino Y, Yamamuro A et al (2022) Dopamine inhibits the expression of proinflammatory cytokines of microglial cells through the formation of dopamine quinone in the mouse striatum. J Pharmacol Sci 148:41\u201350. https:\/\/doi.org\/10.1016\/j.jphs.2021.10.004","journal-title":"J Pharmacol Sci"},{"key":"6040_CR91","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.biopsych.2020.11.018","volume":"89","author":"H Wang","year":"2021","unstructured":"Wang H, Tan YZ, Mu RH et al (2021) Takeda G protein\u2013coupled receptor 5 modulates depression-like behaviors via hippocampal CA3 pyramidal neurons afferent to dorsolateral septum. Biol Psychiatry 89:1084\u20131095. https:\/\/doi.org\/10.1016\/j.biopsych.2020.11.018","journal-title":"Biol Psychiatry"},{"key":"6040_CR92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/nu14132707","volume":"14","author":"J Gillard","year":"2022","unstructured":"Gillard J, Picalausa C, Ullmer C et al (2022) Enterohepatic Takeda G-protein coupled receptor 5 agonism in metabolic dysfunction-associated fatty liver disease and related glucose dysmetabolism. Nutrients 14:1\u201317. https:\/\/doi.org\/10.3390\/nu14132707","journal-title":"Nutrients"},{"key":"6040_CR93","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.immuni.2016.09.008","volume":"45","author":"C Guo","year":"2016","unstructured":"Guo C, Xie S, Chi Z et al (2016) Bile acids control inflammation and metabolic disorder through inhibition of NLRP3 inflammasome. Immunity 45:802\u2013816. https:\/\/doi.org\/10.1016\/j.immuni.2016.09.008","journal-title":"Immunity"},{"key":"6040_CR94","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/3716609","volume":"2022","author":"R Mu","year":"2022","unstructured":"Mu R, Wu X, Yuan D et al (2022) Activation of TGR5 ameliorates streptozotocin-induced cognitive impairment by modulating apoptosis, neurogenesis, and neuronal firing. Oxid Med Cell Longev 2022:1\u201323. https:\/\/doi.org\/10.1155\/2022\/3716609","journal-title":"Oxid Med Cell Longev"},{"key":"6040_CR95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-021-02087-1","volume":"18","author":"H Liang","year":"2021","unstructured":"Liang H, Matei N, McBride DW et al (2021) TGR5 activation attenuates neuroinflammation via Pellino3 inhibition of caspase-8\/NLRP3 after middle cerebral artery occlusion in rats. J Neuroinflammation 18:1\u201313. https:\/\/doi.org\/10.1186\/s12974-021-02087-1","journal-title":"J Neuroinflammation"},{"key":"6040_CR96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12929-020-00656-9","volume":"27","author":"H Liang","year":"2020","unstructured":"Liang H, Matei N, McBride DW et al (2020) Activation of TGR5 protects blood brain barrier via the BRCA1\/Sirt1 pathway after middle cerebral artery occlusion in rats. J Biomed Sci 27:1\u201311. https:\/\/doi.org\/10.1186\/s12929-020-00656-9","journal-title":"J Biomed Sci"},{"key":"6040_CR97","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.nbd.2018.09.006","volume":"126","author":"SM Stamatovic","year":"2019","unstructured":"Stamatovic SM, Martinez-Revollar G, Hu A et al (2019) Decline in Sirtuin-1 expression and activity plays a critical role in blood-brain barrier permeability in aging. Neurobiol Dis 126:105\u2013116. https:\/\/doi.org\/10.1016\/j.nbd.2018.09.006","journal-title":"Neurobiol Dis"},{"key":"6040_CR98","doi-asserted-by":"publisher","first-page":"7130","DOI":"10.1128\/mcb.24.16.7130-7139.2004","volume":"24","author":"A Kobayashi","year":"2004","unstructured":"Kobayashi A, Kang M-I, Okawa H et al (2004) Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol 24:7130\u20137139. https:\/\/doi.org\/10.1128\/mcb.24.16.7130-7139.2004","journal-title":"Mol Cell Biol"},{"key":"6040_CR99","doi-asserted-by":"publisher","first-page":"11624","DOI":"10.1038\/ncomms11624","volume":"7","author":"EH Kobayashi","year":"2016","unstructured":"Kobayashi EH, Suzuki T, Funayama R et al (2016) Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription. Nat Commun 7:11624. https:\/\/doi.org\/10.1038\/ncomms11624","journal-title":"Nat Commun"},{"key":"6040_CR100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.34172\/ps.2022.23","volume":"29","author":"E Rymbai","year":"2022","unstructured":"Rymbai E, Sugumar D, Selvaraj J et al (2022) Modulation of Nrf2 by activation of estrogen receptor \u03b2 as a therapeutic strategy to prevent cancer development and overcome inflammation-related drug resistance in breast cancer. Pharm Sci 29:1\u201319. https:\/\/doi.org\/10.34172\/ps.2022.23","journal-title":"Pharm Sci"},{"key":"6040_CR101","doi-asserted-by":"publisher","first-page":"184","DOI":"10.36468\/pharmaceutical-sciences.638","volume":"82","author":"D Sugumar","year":"2020","unstructured":"Sugumar D, Saravanan J, Emdormi R, Praveen TK (2020) An update on the role of Nrf2 and its activators in diseases associated with oxidative stress. Indian J Pharm Sci 82:184\u2013192","journal-title":"Indian J Pharm Sci"},{"key":"6040_CR102","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1089\/ars.2015.6615","volume":"26","author":"X Liu","year":"2017","unstructured":"Liu X, Zhang X, Ding Y et al (2017) Nuclear factor E2-related factor-2 negatively regulates NLRP3 inflammasome activity by inhibiting reactive oxygen species-induced NLRP3 priming. Antioxid Redox Signal 26:28\u201343. https:\/\/doi.org\/10.1089\/ars.2015.6615","journal-title":"Antioxid Redox Signal"},{"key":"6040_CR103","doi-asserted-by":"publisher","first-page":"6277","DOI":"10.2147\/JIR.S478683","volume":"17","author":"R Lu","year":"2024","unstructured":"Lu R, Zhou X, Zhang L et al (2024) Nrf2 deficiency exacerbates Parkinson\u2019s disease by aggravating NLRP3 inflammasome activation in MPTP-induced mouse models and LPS-induced BV2 cells. J Inflamm Res 17:6277\u20136295. https:\/\/doi.org\/10.2147\/JIR.S478683","journal-title":"J Inflamm Res"},{"key":"6040_CR104","doi-asserted-by":"publisher","first-page":"105014","DOI":"10.1016\/j.neuint.2021.105014","volume":"145","author":"S Jayaram","year":"2021","unstructured":"Jayaram S, Krishnamurthy PT (2021) Role of microgliosis, oxidative stress and associated neuroinflammation in the pathogenesis of Parkinson\u2019s disease: the therapeutic role of Nrf2 activators. Neurochem Int 145:105014. https:\/\/doi.org\/10.1016\/j.neuint.2021.105014","journal-title":"Neurochem Int"},{"key":"6040_CR105","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.neuroscience.2020.08.004","volume":"446","author":"YQ Yan","year":"2020","unstructured":"Yan YQ, Fang Y, Zheng R et al (2020) NLRP3 inflammasomes in Parkinson\u2019s disease and their regulation by Parkin. Neuroscience 446:323\u2013334. https:\/\/doi.org\/10.1016\/j.neuroscience.2020.08.004","journal-title":"Neuroscience"},{"key":"6040_CR106","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1002\/glia.23337","volume":"66","author":"F Mouton-Liger","year":"2018","unstructured":"Mouton-Liger F, Rosazza T, Sepulveda-Diaz J et al (2018) Parkin deficiency modulates NLRP3 inflammasome activation by attenuating an A20-dependent negative feedback loop. Glia 66:1736\u20131751. https:\/\/doi.org\/10.1002\/glia.23337","journal-title":"Glia"},{"key":"6040_CR107","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.redox.2019.101254","volume":"26","author":"Q Lin","year":"2019","unstructured":"Lin Q, Li S, Jiang N et al (2019) PINK1-parkin pathway of mitophagy protects against contrast-induced acute kidney injury via decreasing mitochondrial ROS and NLRP3 inflammasome activation. Redox Biol 26:1\u201316. https:\/\/doi.org\/10.1016\/j.redox.2019.101254","journal-title":"Redox Biol"},{"key":"6040_CR108","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1136\/jmg.2008.063917","volume":"46","author":"J Brooks","year":"2009","unstructured":"Brooks J, Ding J, Simon-Sanchez J et al (2009) Parkin and PINK1 mutations in early-onset Parkinson\u2019s disease: comprehensive screening in publicly available cases and control. J Med Genet 46:375\u2013381. https:\/\/doi.org\/10.1136\/jmg.2008.063917","journal-title":"J Med Genet"},{"key":"6040_CR109","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1016\/S1353-8020(13)70011-7","volume":"20","author":"M Spatola","year":"2014","unstructured":"Spatola M, Wider C (2014) Genetics of Parkinson\u2019s disease: the yield. Parkinsonism Relat Disord 20:S35\u2013S38. https:\/\/doi.org\/10.1016\/S1353-8020(13)70011-7","journal-title":"Parkinsonism Relat Disord"},{"key":"6040_CR110","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1002\/mds.29025","volume":"37","author":"K Wasner","year":"2022","unstructured":"Wasner K, Smajic S, Ghelfi J et al (2022) Parkin deficiency impairs mitochondrial DNA dynamics and propagates inflammation. Mov Disord 37:1405\u20131415. https:\/\/doi.org\/10.1002\/mds.29025","journal-title":"Mov Disord"},{"key":"6040_CR111","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/acel.13834","volume":"22","author":"YQ Yan","year":"2023","unstructured":"Yan YQ, Zheng R, Liu Y et al (2023) Parkin regulates microglial NLRP3 and represses neurodegeneration in Parkinson\u2019s disease. Aging Cell 22:1\u201314. https:\/\/doi.org\/10.1111\/acel.13834","journal-title":"Aging Cell"},{"key":"6040_CR112","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.freeradbiomed.2020.09.015","volume":"160","author":"Y Xu","year":"2020","unstructured":"Xu Y, Tang Y, Lu J et al (2020) PINK1-mediated mitophagy protects against hepatic ischemia\/reperfusion injury by restraining NLRP3 inflammasome activation. Free Radic Biol Med 160:871\u2013886. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2020.09.015","journal-title":"Free Radic Biol Med"},{"key":"6040_CR113","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.immuni.2014.12.031","volume":"42","author":"BH Duong","year":"2015","unstructured":"Duong BH, Onizawa M, Oses-Prieto JA et al (2015) A20 restricts ubiquitination of pro-interleukin-1\u03b2 protein complexes and suppresses NLRP3 inflammasome activity. Immunity 42:55\u201367. https:\/\/doi.org\/10.1016\/j.immuni.2014.12.031","journal-title":"Immunity"},{"key":"6040_CR114","doi-asserted-by":"publisher","first-page":"119243","DOI":"10.1016\/j.bbamcr.2022.119243","volume":"1869","author":"A Drobny","year":"2022","unstructured":"Drobny A, Prieto Huarcaya S, Dobert J et al (2022) The role of lysosomal cathepsins in neurodegeneration: mechanistic insights, diagnostic potential and therapeutic approaches. Biochim Biophys Acta Mol Cell Res 1869:119243. https:\/\/doi.org\/10.1016\/j.bbamcr.2022.119243","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"6040_CR115","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnagi.2024.1380483","volume":"16","author":"A Yusufujiang","year":"2024","unstructured":"Yusufujiang A, Zeng S, Li H (2024) Cathepsins and Parkinson\u2019s disease: insights from Mendelian randomization analyses. Front Aging Neurosci 16:1\u20139. https:\/\/doi.org\/10.3389\/fnagi.2024.1380483","journal-title":"Front Aging Neurosci"},{"key":"6040_CR116","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/brainsci14050482","volume":"14","author":"C Lu","year":"2024","unstructured":"Lu C, Cai X, Zhi S et al (2024) Exploring the association between cathepsin B and Parkinson\u2019s disease. Brain Sci 14:1\u201311. https:\/\/doi.org\/10.3390\/brainsci14050482","journal-title":"Brain Sci"},{"key":"6040_CR117","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2024.1394807","author":"L Lin","year":"2024","unstructured":"Lin L, Wu Z, Luo H, Huang Y (2024) Cathepsin-mediated regulation of alpha-synuclein in Parkinson\u2019s disease: a Mendelian randomization study. Front Aging Neurosci. https:\/\/doi.org\/10.3389\/fnagi.2024.1394807","journal-title":"Front Aging Neurosci"},{"key":"6040_CR118","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.nbd.2014.10.011","volume":"73","author":"A Tsujimura","year":"2015","unstructured":"Tsujimura A, Taguchi K, Watanabe Y et al (2015) Lysosomal enzyme cathepsin B enhances the aggregate forming activity of exogenous \u03b1-synuclein fibrils. Neurobiol Dis 73:244\u2013253. https:\/\/doi.org\/10.1016\/j.nbd.2014.10.011","journal-title":"Neurobiol Dis"},{"key":"6040_CR119","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fcell.2020.00167","volume":"8","author":"A Chevriaux","year":"2020","unstructured":"Chevriaux A, Pilot T, Derang\u00e8re V et al (2020) Cathepsin B is required for NLRP3 inflammasome activation in macrophages, through NLRP3 interaction. Front Cell Dev Biol 8:1\u20138. https:\/\/doi.org\/10.3389\/fcell.2020.00167","journal-title":"Front Cell Dev Biol"},{"key":"6040_CR120","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nm.2999","volume":"19","author":"M Bruchard","year":"2013","unstructured":"Bruchard M, Mignot G, Derang\u00e8re V et al (2013) Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med 19:57\u201364. https:\/\/doi.org\/10.1038\/nm.2999","journal-title":"Nat Med"},{"key":"6040_CR121","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1128\/jvi.01265-10","volume":"85","author":"AU Barlan","year":"2011","unstructured":"Barlan AU, Griffin TM, Mcguire KA, Wiethoff CM (2011) Adenovirus membrane penetration activates the NLRP3 inflammasome. J Virol 85:146\u2013155. https:\/\/doi.org\/10.1128\/jvi.01265-10","journal-title":"J Virol"},{"key":"6040_CR122","doi-asserted-by":"publisher","first-page":"813637","DOI":"10.3389\/fmolb.2022.813637","volume":"9","author":"AB Celi","year":"2022","unstructured":"Celi AB, Goldstein J, Rosato-Siri MV, Pinto A (2022) Role of globotriaosylceramide in physiology and pathology. Front Mol Biosci 9:813637. https:\/\/doi.org\/10.3389\/fmolb.2022.813637","journal-title":"Front Mol Biosci"},{"key":"6040_CR123","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1007\/s00253-015-7236-3","volume":"100","author":"YS Chan","year":"2016","unstructured":"Chan YS, Ng TB (2016) Shiga toxins: from structure and mechanism to applications. Appl Microbiol Biotechnol 100:1597\u20131610. https:\/\/doi.org\/10.1007\/s00253-015-7236-3","journal-title":"Appl Microbiol Biotechnol"},{"key":"6040_CR124","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1128\/IAI.01095-15","volume":"84","author":"MS Lee","year":"2015","unstructured":"Lee MS, Kwon H, Lee EY et al (2015) Shiga toxins activate the NLRP3 inflammasome pathway to promote both production of the proinflammatory cytokine interleukin-1\u03b2 and apoptotic cell death. Infect Immun 84:172\u2013186. https:\/\/doi.org\/10.1128\/IAI.01095-15","journal-title":"Infect Immun"},{"key":"6040_CR125","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13024-020-00408-1","volume":"15","author":"K Belarbi","year":"2020","unstructured":"Belarbi K, Cuvelier E, Bonte MA et al (2020) Glycosphingolipids and neuroinflammation in Parkinson\u2019s disease. Mol Neurodegener 15:59. https:\/\/doi.org\/10.1186\/s13024-020-00408-1","journal-title":"Mol Neurodegener"},{"key":"6040_CR126","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s10719-021-10023-x","volume":"39","author":"KL Wallom","year":"2022","unstructured":"Wallom KL, Fern\u00e1ndez-Su\u00e1rez ME, Priestman DA et al (2022) Glycosphingolipid metabolism and its role in ageing and Parkinson\u2019s disease. Glycoconj J 39:39\u201353. https:\/\/doi.org\/10.1007\/s10719-021-10023-x","journal-title":"Glycoconj J"},{"key":"6040_CR127","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.tem.2018.11.003","volume":"30","author":"G Lin","year":"2019","unstructured":"Lin G, Wang L, Marcogliese PC, Bellen HJ (2019) Sphingolipids in the pathogenesis of Parkinson\u2019s disease and parkinsonism. Trends Endocrinol Metab 30:106\u2013117. https:\/\/doi.org\/10.1016\/j.tem.2018.11.003","journal-title":"Trends Endocrinol Metab"},{"key":"6040_CR128","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ymgmr.2017.10.013","volume":"14","author":"AH Wise","year":"2018","unstructured":"Wise AH, Yang A, Naik H et al (2018) Parkinson\u2019s disease prevalence in Fabry disease: a survey study. Mol Genet Metab Rep 14:27\u201330. https:\/\/doi.org\/10.1016\/j.ymgmr.2017.10.013","journal-title":"Mol Genet Metab Rep"},{"key":"6040_CR129","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.3390\/biomedicines10123132","volume":"10","author":"M Zedde","year":"2022","unstructured":"Zedde M, Pascarella R, Cavallieri F et al (2022) Anderson\u2013Fabry disease: a new piece of the lysosomal puzzle in Parkinson disease? Biomedicines 10:3132. https:\/\/doi.org\/10.3390\/biomedicines10123132","journal-title":"Biomedicines"},{"key":"6040_CR130","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.3390\/cells13131131","volume":"13","author":"M Zedde","year":"2024","unstructured":"Zedde M, Romani I, Scaravilli A et al (2024) Expanding the neurological phenotype of Anderson-Fabry disease: proof of concept for an extrapyramidal neurodegenerative pattern and comparison with monogenic vascular parkinsonism. Cells 13:1131. https:\/\/doi.org\/10.3390\/cells13131131","journal-title":"Cells"},{"key":"6040_CR131","doi-asserted-by":"publisher","first-page":"e157782","DOI":"10.1172\/JCI157782","volume":"133","author":"F Braun","year":"2023","unstructured":"Braun F, Abed A, Sellung D et al (2023) Accumulation of \u03b1-synuclein mediates podocyte injury in Fabry nephropathy. J Clin Invest 133:e157782. https:\/\/doi.org\/10.1172\/JCI157782","journal-title":"J Clin Invest"},{"key":"6040_CR132","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3969\/j.issn.1673-5374.2012.02.011","volume":"7","author":"L Zhang","year":"2012","unstructured":"Zhang L, Dong Y, Xu X, Xu Z (2012) The role of autophagy in Parkinson\u2019s disease. Neural Regen Res 7:141\u2013145. https:\/\/doi.org\/10.3969\/j.issn.1673-5374.2012.02.011","journal-title":"Neural Regen Res"},{"key":"6040_CR133","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s13760-021-01814-y","volume":"122","author":"J Han","year":"2022","unstructured":"Han J, Feng G, Wu J et al (2022) Association of ATG5 gene polymorphism with Parkinson\u2019s disease in a Han Chinese population. Acta Neurol Belg 122:1049\u20131056. https:\/\/doi.org\/10.1007\/s13760-021-01814-y","journal-title":"Acta Neurol Belg"},{"key":"6040_CR134","doi-asserted-by":"publisher","first-page":"18062","DOI":"10.1074\/jbc.M116.764795","volume":"292","author":"ZY Hu","year":"2017","unstructured":"Hu ZY, Chen B, Zhang JP, Ma YY (2017) Up-regulation of autophagy-related gene 5 (ATG5) protects dopaminergic neurons in a zebrafish model of Parkinson\u2019s disease. J Biol Chem 292:18062\u201318074. https:\/\/doi.org\/10.1074\/jbc.M116.764795","journal-title":"J Biol Chem"},{"key":"6040_CR135","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.neurobiolaging.2017.11.006","volume":"63","author":"Y Miki","year":"2018","unstructured":"Miki Y, Shimoyama S, Kon T et al (2018) Alteration of autophagy-related proteins in peripheral blood mononuclear cells of patients with Parkinson\u2019s disease. Neurobiol Aging 63:33\u201343. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2017.11.006","journal-title":"Neurobiol Aging"},{"key":"6040_CR136","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-023-02830-w","volume":"20","author":"J Amo-Aparicio","year":"2023","unstructured":"Amo-Aparicio J, Daly J, H\u00f8jen JF, Dinarello CA (2023) Pharmacologic inhibition of NLRP3 reduces the levels of \u03b1-synuclein and protects dopaminergic neurons in a model of Parkinson\u2019s disease. J Neuroinflammation 20:1\u201314. https:\/\/doi.org\/10.1186\/s12974-023-02830-w","journal-title":"J Neuroinflammation"},{"key":"6040_CR137","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1080\/15548627.2019.1596481","volume":"15","author":"X Han","year":"2019","unstructured":"Han X, Sun S, Sun Y et al (2019) Small molecule-driven NLRP3 inflammation inhibition via interplay between ubiquitination and autophagy: implications for Parkinson disease. Autophagy 15:1860\u20131881. https:\/\/doi.org\/10.1080\/15548627.2019.1596481","journal-title":"Autophagy"},{"key":"6040_CR138","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1083\/jcb.201503023","volume":"210","author":"T Kimura","year":"2015","unstructured":"Kimura T, Jain A, Choi SW et al (2015) TRIM-mediated precision autophagy targets cytoplasmic regulators of innate immunity. J Cell Biol 210:973\u2013989. https:\/\/doi.org\/10.1083\/jcb.201503023","journal-title":"J Cell Biol"},{"key":"6040_CR139","doi-asserted-by":"publisher","first-page":"108729","DOI":"10.1016\/j.pharmthera.2024.108729","volume":"263","author":"Y Zheng","year":"2024","unstructured":"Zheng Y, Zhou Z, Liu M, Chen Z (2024) Targeting selective autophagy in CNS disorders by small-molecule compounds. Pharmacol Ther 263:108729. https:\/\/doi.org\/10.1016\/j.pharmthera.2024.108729","journal-title":"Pharmacol Ther"},{"key":"6040_CR140","doi-asserted-by":"publisher","first-page":"40817","DOI":"10.18632\/oncotarget.17256","volume":"8","author":"JH Ko","year":"2017","unstructured":"Ko JH, Yoon S-O, Lee HJ, Oh JY (2017) Rapamycin regulates macrophage activation by inhibiting NLRP3 inflammasome-p38 MAPK-NF\u03baB pathways in autophagy-and p62-dependent manners. Oncotarget 8:40817\u201340831. https:\/\/doi.org\/10.18632\/oncotarget.17256","journal-title":"Oncotarget"},{"key":"6040_CR141","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1038\/nm.4222","volume":"22","author":"T Eisenberg","year":"2016","unstructured":"Eisenberg T, Abdellatif M, Schroeder S et al (2016) Cardioprotection and lifespan extension by the natural polyamine spermidine. Nat Med 22:1428\u20131438. https:\/\/doi.org\/10.1038\/nm.4222","journal-title":"Nat Med"},{"key":"6040_CR142","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.immuni.2021.05.004","volume":"54","author":"H Xian","year":"2021","unstructured":"Xian H, Liu Y, Rundberg Nilsson A et al (2021) Metformin inhibition of mitochondrial ATP and DNA synthesis abrogates NLRP3 inflammasome activation and pulmonary inflammation. Immunity 54:1463-1477.e11. https:\/\/doi.org\/10.1016\/j.immuni.2021.05.004","journal-title":"Immunity"},{"key":"6040_CR143","doi-asserted-by":"publisher","first-page":"e043374","DOI":"10.1161\/JAHA.125.043374","volume":"15","author":"Z Zhou","year":"2026","unstructured":"Zhou Z, Liu M, Fangma Y et al (2026) Peiminine\u2010induced selective autophagy of AIM2 inflammasomes rescues cerebral ischemic injury. J Am Heart Assoc 15:e043374. https:\/\/doi.org\/10.1161\/JAHA.125.043374","journal-title":"J Am Heart Assoc"},{"key":"6040_CR144","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/6682336","volume":"2021","author":"E Gorostieta-Salas","year":"2021","unstructured":"Gorostieta-Salas E, Moreno-Blas D, Geronimo-Olvera C et al (2021) Enhanced activity of exportin-1\/CRM1 in neurons contributes to autophagy dysfunction and senescent features in old mouse brain. Oxid Med Cell Longev 2021:1\u201325. https:\/\/doi.org\/10.1155\/2021\/6682336","journal-title":"Oxid Med Cell Longev"},{"key":"6040_CR145","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.celrep.2018.04.063","volume":"23","author":"MJ Silvestrini","year":"2018","unstructured":"Silvestrini MJ, Johnson JR, Kumar AV et al (2018) Nuclear export inhibition enhances HLH-30\/TFEB activity, autophagy, and lifespan. Cell Rep 23:1915\u20131921. https:\/\/doi.org\/10.1016\/j.celrep.2018.04.063","journal-title":"Cell Rep"},{"key":"6040_CR146","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2022.847605","volume":"13","author":"S Liu","year":"2022","unstructured":"Liu S, Wang S, Gu R et al (2022) The XPO1 inhibitor KPT-8602 ameliorates Parkinson\u2019s disease by inhibiting the NF-\u03baB\/NLRP3 pathway. Front Pharmacol 13:1\u201314. https:\/\/doi.org\/10.3389\/fphar.2022.847605","journal-title":"Front Pharmacol"},{"key":"6040_CR147","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/brb3.2680","volume":"12","author":"G Luo","year":"2022","unstructured":"Luo G, Wang X, Liu C (2022) MiR-483-3p improves learning and memory abilities via XPO1 in Alzheimer\u2019s disease. Brain Behav 12:1\u201315. https:\/\/doi.org\/10.1002\/brb3.2680","journal-title":"Brain Behav"},{"key":"6040_CR148","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2022.991059","volume":"13","author":"V Sharma","year":"2022","unstructured":"Sharma V, Patial V (2022) Peroxisome proliferator-activated receptor gamma and its natural agonists in the treatment of kidney diseases. Front Pharmacol 13:1\u201318. https:\/\/doi.org\/10.3389\/fphar.2022.991059","journal-title":"Front Pharmacol"},{"key":"6040_CR149","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s12035-012-8259-8","volume":"46","author":"YC Chen","year":"2012","unstructured":"Chen YC, Wu JS, Da TH et al (2012) Peroxisome proliferator-activated receptor gamma (PPAR-\u03b3) and neurodegenerative disorders. Mol Neurobiol 46:114\u2013124. https:\/\/doi.org\/10.1007\/s12035-012-8259-8","journal-title":"Mol Neurobiol"},{"key":"6040_CR150","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.7150\/thno.46873","volume":"11","author":"CC Yang","year":"2021","unstructured":"Yang CC, Wu CH, Lin TC et al (2021) Inhibitory effect of PPAR\u03b3 on NLRP3 inflammasome activation. Theranostics 11:2424\u20132441. https:\/\/doi.org\/10.7150\/thno.46873","journal-title":"Theranostics"},{"key":"6040_CR151","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/6386729","volume":"2019","author":"QQ Meng","year":"2019","unstructured":"Meng QQ, Feng ZC, Zhang XL et al (2019) PPAR-\u03b3 Activation exerts an anti-inflammatory effect by suppressing the NLRP3 inflammasome in spinal cord-derived neurons. Mediators Inflamm 2019:1\u201312. https:\/\/doi.org\/10.1155\/2019\/6386729","journal-title":"Mediators Inflamm"},{"key":"6040_CR152","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-8-91","author":"CR Swanson","year":"2011","unstructured":"Swanson CR, Joers V, Bondarenko V et al (2011) The PPAR-\u03b3 agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys. J Neuroinflammation. https:\/\/doi.org\/10.1186\/1742-2094-8-91","journal-title":"J Neuroinflammation"},{"key":"6040_CR153","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1046\/j.1471-4159.2002.00990.x","volume":"82","author":"T Breidert","year":"2002","unstructured":"Breidert T, Callebert J, Heneka MT et al (2002) Protective action of the peroxisome proliferator-activated receptor-\u03b3 agonist pioglitazone in a mouse model of Parkinson\u2019s disease. J Neurochem 82:615\u2013624. https:\/\/doi.org\/10.1046\/j.1471-4159.2002.00990.x","journal-title":"J Neurochem"},{"key":"6040_CR154","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fncel.2019.00466","volume":"13","author":"P Yin","year":"2019","unstructured":"Yin P, Wang X, Wang S et al (2019) Maresin 1 improves cognitive decline and ameliorates inflammation in a mouse model of Alzheimer\u2019s disease. Front Cell Neurosci 13:1\u201313. https:\/\/doi.org\/10.3389\/fncel.2019.00466","journal-title":"Front Cell Neurosci"},{"key":"6040_CR155","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-022-02405-1","volume":"19","author":"J Wei","year":"2022","unstructured":"Wei J, Su W, Zhao Y et al (2022) Maresin 1 promotes nerve regeneration and alleviates neuropathic pain after nerve injury. J Neuroinflammation 19:1\u201316. https:\/\/doi.org\/10.1186\/s12974-022-02405-1","journal-title":"J Neuroinflammation"},{"key":"6040_CR156","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-022-02386-1","volume":"19","author":"A S\u00e1nchez-Fern\u00e1ndez","year":"2022","unstructured":"S\u00e1nchez-Fern\u00e1ndez A, Zandee S, Mastrogiovanni M et al (2022) Administration of Maresin-1 ameliorates the physiopathology of experimental autoimmune encephalomyelitis. J Neuroinflammation 19:1\u201318. https:\/\/doi.org\/10.1186\/s12974-022-02386-1","journal-title":"J Neuroinflammation"},{"key":"6040_CR157","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/aps.2014.109","volume":"36","author":"XK Zhang","year":"2015","unstructured":"Zhang XK, Su Y, Chen L et al (2015) Regulation of the nongenomic actions of retinoid X receptor-\u03b1 by targeting the coregulator-binding sites. Acta Pharmacol Sin 36:102\u2013112. https:\/\/doi.org\/10.1038\/aps.2014.109","journal-title":"Acta Pharmacol Sin"},{"key":"6040_CR158","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1194\/jlr.M053058","volume":"56","author":"L Sun","year":"2015","unstructured":"Sun L, Xu YW, Han J et al (2015) 12\/15-Lipoxygenase metabolites of arachidonic acid activate PPAR\u03b3: a possible neuroprotective effect in ischemic brain. J Lipid Res 56:502\u2013514. https:\/\/doi.org\/10.1194\/jlr.M053058","journal-title":"J Lipid Res"},{"key":"6040_CR159","doi-asserted-by":"publisher","first-page":"11944","DOI":"10.1096\/fj.202000665RR","volume":"34","author":"S Zheng","year":"2020","unstructured":"Zheng S, Ma M, Li Z et al (2020) Posttreatment of Maresin1 inhibits NLRP3 inflammasome activation via promotion of NLRP3 ubiquitination. FASEB J 34:11944\u201311956. https:\/\/doi.org\/10.1096\/fj.202000665RR","journal-title":"FASEB J"},{"key":"6040_CR160","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/cshperspect.a011148","volume":"4","author":"P Sassone-Corsi","year":"2012","unstructured":"Sassone-Corsi P (2012) The cyclic AMP pathway. Cold Spring Harb Perspect Biol 4:1\u20133. https:\/\/doi.org\/10.1101\/cshperspect.a011148","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"6040_CR161","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/npp.2012.112","volume":"38","author":"LD Moore","year":"2013","unstructured":"Moore LD, Le T, Fan G (2013) DNA methylation and its basic function. Neuropsychopharmacology (New York) 38:23\u201338. https:\/\/doi.org\/10.1038\/npp.2012.112","journal-title":"Neuropsychopharmacology (New York)"},{"key":"6040_CR162","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/4323281","volume":"2016","author":"M Wei","year":"2016","unstructured":"Wei M, Wang L, Wu T et al (2016) NLRP3 activation was regulated by DNA methylation modification during Mycobacterium tuberculosis infection. Biomed Res Int 2016:1\u201310. https:\/\/doi.org\/10.1155\/2016\/4323281","journal-title":"Biomed Res Int"},{"key":"6040_CR163","doi-asserted-by":"publisher","first-page":"50074","DOI":"10.18632\/oncotarget.10317","volume":"7","author":"CS Wu","year":"2016","unstructured":"Wu CS, Chang KP, OuYang CN et al (2016) ASC contributes to metastasis of oral cavity squamous cell carcinoma. Oncotarget 7:50074\u201350085. https:\/\/doi.org\/10.18632\/oncotarget.10317","journal-title":"Oncotarget"},{"key":"6040_CR164","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1111\/cts.12961","volume":"14","author":"M Lucaf\u00f2","year":"2021","unstructured":"Lucaf\u00f2 M, Granata S, Bonten EJ et al (2021) Hypomethylation of NLRP3 gene promoter discriminates glucocorticoid-resistant from glucocorticoid-sensitive idiopathic nephrotic syndrome patients. Clin Transl Sci 14:964\u2013975. https:\/\/doi.org\/10.1111\/cts.12961","journal-title":"Clin Transl Sci"},{"key":"6040_CR165","doi-asserted-by":"publisher","first-page":"4175","DOI":"10.4049\/jimmunol.1201516","volume":"189","author":"F Bauernfeind","year":"2012","unstructured":"Bauernfeind F, Rieger A, Schildberg FA et al (2012) NLRP3 inflammasome activity is negatively controlled by miR-223. J Immunol 189:4175\u20134181. https:\/\/doi.org\/10.4049\/jimmunol.1201516","journal-title":"J Immunol"},{"key":"6040_CR166","doi-asserted-by":"publisher","first-page":"e3170","DOI":"10.1038\/CDDIS.2017.549","volume":"8","author":"Z Feng","year":"2017","unstructured":"Feng Z, Qi S, Zhang Y et al (2017) Ly6G+ neutrophil-derived miR-223 inhibits the NLRP3 inflammasome in mitochondrial DAMP-induced acute lung injury. Cell Death Dis 8:e3170. https:\/\/doi.org\/10.1038\/CDDIS.2017.549","journal-title":"Cell Death Dis"},{"key":"6040_CR167","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1038\/s41467-019-09482-6","volume":"10","author":"P Zhang","year":"2019","unstructured":"Zhang P, Cao L, Zhou R et al (2019) The lncRNA Neat1 promotes activation of inflammasomes in macrophages. Nat Commun 10:1495. https:\/\/doi.org\/10.1038\/s41467-019-09482-6","journal-title":"Nat Commun"},{"key":"6040_CR168","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/s41419-021-04180-y","volume":"12","author":"D Luo","year":"2021","unstructured":"Luo D, Dai W, Feng X et al (2021) Suppression of lncRNA NLRP3 inhibits NLRP3-triggered inflammatory responses in early acute lung injury. Cell Death Dis 12:898. https:\/\/doi.org\/10.1038\/s41419-021-04180-y","journal-title":"Cell Death Dis"},{"key":"6040_CR169","doi-asserted-by":"publisher","first-page":"e28939","DOI":"10.1002\/jmv.28939","volume":"95","author":"Q Hu","year":"2023","unstructured":"Hu Q, Gao Y, Xie Y et al (2023) Mechanism of RNA m6A methylation modification regulating NLRP3 inflammasome activation for hand, foot, and mouth disease progression. J Med Virol 95:e28939. https:\/\/doi.org\/10.1002\/jmv.28939","journal-title":"J Med Virol"},{"key":"6040_CR170","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41590-018-0275-z","volume":"20","author":"R Winkler","year":"2019","unstructured":"Winkler R, Gillis E, Lasman L et al (2019) m6A modification controls the innate immune response to infection by targeting type I interferons. Nat Immunol 20:173\u2013182. https:\/\/doi.org\/10.1038\/s41590-018-0275-z","journal-title":"Nat Immunol"},{"key":"6040_CR171","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-26142-w","volume":"12","author":"T Niu","year":"2021","unstructured":"Niu T, De RC, Chautard S et al (2021) NLRP3 phosphorylation in its LRR domain critically regulates inflammasome assembly. Nat Commun 12:1\u201315. https:\/\/doi.org\/10.1038\/s41467-021-26142-w","journal-title":"Nat Commun"},{"key":"6040_CR172","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.molcel.2017.08.017","volume":"68","author":"N Song","year":"2017","unstructured":"Song N, Liu Z-S, Xue W et al (2017) NLRP3 phosphorylation is an essential priming event for inflammasome activation. Mol Cell 68:185-197.e6. https:\/\/doi.org\/10.1016\/j.molcel.2017.08.017","journal-title":"Mol Cell"},{"key":"6040_CR173","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1084\/jem.20162040","volume":"214","author":"Z Zhang","year":"2017","unstructured":"Zhang Z, Meszaros G, He W et al (2017) Protein kinase D at the Golgi controls NLRP3 inflammasome activation. J Exp Med 214:2671\u20132693. https:\/\/doi.org\/10.1084\/jem.20162040","journal-title":"J Exp Med"},{"key":"6040_CR174","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1038\/ni.3538","volume":"17","author":"L Mortimer","year":"2016","unstructured":"Mortimer L, Moreau F, MacDonald JA, Chadee K (2016) NLRP3 inflammasome inhibition is disrupted in a group of auto-inflammatory disease CAPS mutations. Nat Immunol 17:1176\u20131186. https:\/\/doi.org\/10.1038\/ni.3538","journal-title":"Nat Immunol"},{"key":"6040_CR175","doi-asserted-by":"publisher","first-page":"EMBR201949666","DOI":"10.15252\/embr.201949666","volume":"21","author":"A Zhang","year":"2020","unstructured":"Zhang A, Xing J, Xia T et al (2020) EphA2 phosphorylates NLRP3 and inhibits inflammasomes in airway epithelial cells. EMBO Rep 21:EMBR201949666. https:\/\/doi.org\/10.15252\/embr.201949666","journal-title":"EMBO Rep"},{"key":"6040_CR176","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s41418-020-00703-w","volume":"28","author":"RB Damgaard","year":"2021","unstructured":"Damgaard RB (2021) The ubiquitin system: from cell signalling to disease biology and new therapeutic opportunities. Cell Death Differ 28:423\u2013426. https:\/\/doi.org\/10.1038\/s41418-020-00703-w","journal-title":"Cell Death Differ"},{"key":"6040_CR177","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-018-03669-z","volume":"9","author":"F Humphries","year":"2018","unstructured":"Humphries F, Bergin R, Jackson R et al (2018) The E3 ubiquitin ligase Pellino2 mediates priming of the NLRP3 inflammasome. Nat Commun 9:1\u201317. https:\/\/doi.org\/10.1038\/s41467-018-03669-z","journal-title":"Nat Commun"},{"key":"6040_CR178","doi-asserted-by":"publisher","first-page":"18124","DOI":"10.1074\/jbc.M115.645549","volume":"290","author":"SH Han","year":"2015","unstructured":"Han SH, Lear TB, Jerome JA et al (2015) Lipopolysaccharide primes the NALP3 inflammasome by inhibiting its ubiquitination and degradation mediated by the SCFFBXL2 E3 ligase. J Biol Chem 290:18124\u201318133. https:\/\/doi.org\/10.1074\/jbc.M115.645549","journal-title":"J Biol Chem"},{"key":"6040_CR179","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1002\/JLB.3MR0720-513R","volume":"108","author":"CM McKee","year":"2020","unstructured":"McKee CM, Coll RC (2020) NLRP3 inflammasome priming: a riddle wrapped in a mystery inside an enigma. J Leukoc Biol 108:937\u2013952. https:\/\/doi.org\/10.1002\/JLB.3MR0720-513R","journal-title":"J Leukoc Biol"},{"key":"6040_CR180","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","volume":"19","author":"KV Swanson","year":"2019","unstructured":"Swanson KV, Deng M, Ting JP-Y (2019) The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol 19:477\u2013489. https:\/\/doi.org\/10.1038\/s41577-019-0165-0","journal-title":"Nat Rev Immunol"},{"key":"6040_CR181","doi-asserted-by":"publisher","first-page":"36617","DOI":"10.1074\/jbc.M112.407130","volume":"287","author":"C Juliana","year":"2012","unstructured":"Juliana C, Fernandes-Alnemri T, Kang S et al (2012) Non-transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation. J Biol Chem 287:36617\u201336622. https:\/\/doi.org\/10.1074\/jbc.M112.407130","journal-title":"J Biol Chem"},{"key":"6040_CR182","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.molcel.2012.11.009","volume":"49","author":"BF Py","year":"2013","unstructured":"Py BF, Kim M-S, Vakifahmetoglu-Norberg H, Yuan J (2013) Deubiquitination of NLRP3 by BRCC3 critically regulates inflammasome activity. Mol Cell 49:331\u2013338. https:\/\/doi.org\/10.1016\/j.molcel.2012.11.009","journal-title":"Mol Cell"},{"key":"6040_CR183","doi-asserted-by":"publisher","first-page":"EMBJ2018100376","DOI":"10.15252\/embj.2018100376","volume":"38","author":"G Ren","year":"2019","unstructured":"Ren G, Zhang X, Xiao Y et al (2019) ABRO1 promotes NLRP3 inflammasome activation through regulation of NLRP3 deubiquitination. EMBO J 38:EMBJ2018100376. https:\/\/doi.org\/10.15252\/embj.2018100376","journal-title":"EMBO J"},{"key":"6040_CR184","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.3389\/fimmu.2019.02783","volume":"10","author":"Z Rao","year":"2019","unstructured":"Rao Z, Chen X, Wu J et al (2019) Vitamin D receptor inhibits NLRP3 activation by impeding its BRCC3-mediated deubiquitination. Front Immunol 10:2783. https:\/\/doi.org\/10.3389\/fimmu.2019.02783","journal-title":"Front Immunol"},{"key":"6040_CR185","doi-asserted-by":"publisher","first-page":"EMBR201744766","DOI":"10.15252\/embr.201744766","volume":"19","author":"P Palaz\u00f3n\u2010Riquelme","year":"2018","unstructured":"Palaz\u00f3n\u2010Riquelme P, Worboys JD, Green J et al (2018) USP7 and USP47 deubiquitinases regulate NLRP3 inflammasome activation. EMBO Rep 19:EMBR201744766. https:\/\/doi.org\/10.15252\/embr.201744766","journal-title":"EMBO Rep"},{"key":"6040_CR186","doi-asserted-by":"publisher","first-page":"e1008335","DOI":"10.1371\/journal.ppat.1008335","volume":"16","author":"W Wang","year":"2020","unstructured":"Wang W, Hu D, Wu C et al (2020) STING promotes NLRP3 localization in ER and facilitates NLRP3 deubiquitination to activate the inflammasome upon HSV-1 infection. PLoS Pathog 16:e1008335. https:\/\/doi.org\/10.1371\/journal.ppat.1008335","journal-title":"PLoS Pathog"},{"key":"6040_CR187","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1096\/fj.201901653R","volume":"34","author":"L Shao","year":"2020","unstructured":"Shao L, Liu Y, Wang W et al (2020) SUMO1 SUMOylates and SENP3 deSUMOylates NLRP3 to orchestrate the inflammasome activation. FASEB J 34:1497\u20131515. https:\/\/doi.org\/10.1096\/fj.201901653R","journal-title":"FASEB J"},{"key":"6040_CR188","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1038\/s41467-018-05321-2","volume":"9","author":"R Barry","year":"2018","unstructured":"Barry R, John SW, Liccardi G et al (2018) SUMO-mediated regulation of NLRP3 modulates inflammasome activity. Nat Commun 9:3001. https:\/\/doi.org\/10.1038\/s41467-018-05321-2","journal-title":"Nat Commun"},{"key":"6040_CR189","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.molcel.2022.12.002","volume":"83","author":"L Wang","year":"2023","unstructured":"Wang L, Cai J, Zhao X et al (2023) Palmitoylation prevents sustained inflammation by limiting NLRP3 inflammasome activation through chaperone-mediated autophagy. Mol Cell 83:281\u2013297. https:\/\/doi.org\/10.1016\/j.molcel.2022.12.002","journal-title":"Mol Cell"},{"key":"6040_CR190","doi-asserted-by":"publisher","first-page":"114070","DOI":"10.1016\/j.celrep.2024.114070","volume":"43","author":"T Yu","year":"2024","unstructured":"Yu T, Hou D, Zhao J et al (2024) NLRP3 Cys126 palmitoylation by ZDHHC7 promotes inflammasome activation. Cell Rep 43:114070. https:\/\/doi.org\/10.1016\/j.celrep.2024.114070","journal-title":"Cell Rep"},{"key":"6040_CR191","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/molecules25235533","volume":"25","author":"LY El-Sharkawy","year":"2020","unstructured":"El-Sharkawy LY, Brough D, Freeman S (2020) Inhibiting the NLRP3 inflammasome. Molecules 25:1\u201314. https:\/\/doi.org\/10.3390\/molecules25235533","journal-title":"Molecules"},{"key":"6040_CR192","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2019.02538","volume":"10","author":"A Zahid","year":"2019","unstructured":"Zahid A, Li B, Kombe AJK et al (2019) Pharmacological inhibitors of the NLRP3 inflammasome. Front Immunol 10:1\u201310. https:\/\/doi.org\/10.3389\/fimmu.2019.02538","journal-title":"Front Immunol"},{"key":"6040_CR193","doi-asserted-by":"publisher","first-page":"111822","DOI":"10.1016\/j.ejmech.2019.111822","volume":"185","author":"X Zhang","year":"2020","unstructured":"Zhang X, Xu A, Lv J et al (2020) Development of small molecule inhibitors targeting NLRP3 inflammasome pathway for inflammatory diseases. Eur J Med Chem 185:111822. https:\/\/doi.org\/10.1016\/j.ejmech.2019.111822","journal-title":"Eur J Med Chem"},{"key":"6040_CR194","doi-asserted-by":"publisher","first-page":"577543","DOI":"10.1016\/j.jneuroim.2021.577543","volume":"354","author":"S Huang","year":"2021","unstructured":"Huang S, Chen Z, Fan B et al (2021) A selective NLRP3 inflammasome inhibitor attenuates behavioral deficits and neuroinflammation in a mouse model of Parkinson\u2019s disease. J Neuroimmunol 354:577543. https:\/\/doi.org\/10.1016\/j.jneuroim.2021.577543","journal-title":"J Neuroimmunol"},{"key":"6040_CR195","doi-asserted-by":"publisher","first-page":"177774","DOI":"10.1016\/j.ejphar.2025.177774","volume":"1001","author":"H Gao","year":"2025","unstructured":"Gao H, Liang Y, Wang M et al (2025) Inhibition of \u03b1-synuclein aggregation by MCC950 attenuates dopaminergic neuronal damage in MN9D cells. Eur J Pharmacol 1001:177774. https:\/\/doi.org\/10.1016\/j.ejphar.2025.177774","journal-title":"Eur J Pharmacol"},{"key":"6040_CR196","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1038\/s41467-018-04947-6","volume":"9","author":"H He","year":"2018","unstructured":"He H, Jiang H, Chen Y et al (2018) Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity. Nat Commun 9:2550. https:\/\/doi.org\/10.1038\/s41467-018-04947-6","journal-title":"Nat Commun"},{"key":"6040_CR197","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1021\/acsptsci.5c00109","volume":"8","author":"W Li","year":"2025","unstructured":"Li W, Zhang J, Chen Q et al (2025) Treatment of Parkinson\u2019s disease with an anti-inflammasome NLRP3 inhibitor derived from a natural product. ACS Pharmacol Transl Sci 8:3896\u20133909. https:\/\/doi.org\/10.1021\/acsptsci.5c00109","journal-title":"ACS Pharmacol Transl Sci"},{"key":"6040_CR198","doi-asserted-by":"publisher","first-page":"107358","DOI":"10.1016\/j.intimp.2020.107358","volume":"92","author":"Y Shi","year":"2021","unstructured":"Shi Y, Lv Q, Zheng M et al (2021) NLRP3 inflammasome inhibitor INF39 attenuated NLRP3 assembly in macrophages. Int Immunopharmacol 92:107358. https:\/\/doi.org\/10.1016\/j.intimp.2020.107358","journal-title":"Int Immunopharmacol"},{"key":"6040_CR199","doi-asserted-by":"publisher","first-page":"4825","DOI":"10.1016\/j.csbj.2023.09.038","volume":"21","author":"B Ahmad","year":"2023","unstructured":"Ahmad B, Achek A, Farooq M, Choi S (2023) Accelerated NLRP3 inflammasome-inhibitory peptide design using a recurrent neural network model and molecular dynamics simulations. Comput Struct Biotechnol J 21:4825\u20134835. https:\/\/doi.org\/10.1016\/j.csbj.2023.09.038","journal-title":"Comput Struct Biotechnol J"},{"key":"6040_CR200","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.3390\/ijms23031651","volume":"23","author":"SM Ghafary","year":"2022","unstructured":"Ghafary SM, Soriano-Teruel PM, Lotfollahzadeh S et al (2022) Identification of NLRP3PYD homo-oligomerization inhibitors with anti-inflammatory activity. Int J Mol Sci 23:1651. https:\/\/doi.org\/10.3390\/ijms23031651","journal-title":"Int J Mol Sci"},{"key":"6040_CR201","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/imm.13375","volume":"163","author":"JG de Souza","year":"2021","unstructured":"de Souza JG, Starobinas N, Iba\u00f1ez OCM (2021) Unknown\/enigmatic functions of extracellular ASC. Immunology 163:377\u2013388. https:\/\/doi.org\/10.1111\/imm.13375","journal-title":"Immunology"},{"key":"6040_CR202","doi-asserted-by":"publisher","first-page":"444","DOI":"10.3389\/fnins.2020.00444","volume":"14","author":"W Cui","year":"2020","unstructured":"Cui W, Sun C, Ma Y et al (2020) Inhibition of TLR4 induces M2 microglial polarization and provides neuroprotection via the NLRP3 inflammasome in Alzheimer\u2019s disease. Front Neurosci 14:444. https:\/\/doi.org\/10.3389\/fnins.2020.00444","journal-title":"Front Neurosci"},{"key":"6040_CR203","doi-asserted-by":"publisher","first-page":"114429","DOI":"10.1016\/j.intimp.2025.114429","volume":"153","author":"X Li","year":"2025","unstructured":"Li X, Yang L, Kang X et al (2025) TAK-242 attenuates NLRP3-ASC inflammasome-mediated neuroinflammation via TLR4\/NF-\u03baB pathway in rat experimental autoimmune neuritis. Int Immunopharmacol 153:114429. https:\/\/doi.org\/10.1016\/j.intimp.2025.114429","journal-title":"Int Immunopharmacol"},{"key":"6040_CR204","doi-asserted-by":"publisher","first-page":"150579","DOI":"10.1016\/j.ijbiomac.2026.150579","volume":"346","author":"Y Cheng","year":"2026","unstructured":"Cheng Y, Wen Y, Wang Z et al (2026) Anti-Parkinson\u2019s disease polysaccharide PFP50-1 attenuated neuroinflammation via inhibition of TLR4\/NF-\u03baB and PI3K\/Akt pathways and suppression of NLRP3 inflammasome activation. Int J Biol Macromol 346:150579. https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.150579","journal-title":"Int J Biol Macromol"},{"key":"6040_CR205","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1016\/S0140-6736(17)32247-X","volume":"390","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, MacFadyen JG, Thuren T et al (2017) Effect of interleukin-1\u03b2 inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet 390:1833\u20131842. https:\/\/doi.org\/10.1016\/S0140-6736(17)32247-X","journal-title":"Lancet"},{"key":"6040_CR206","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1182\/blood-2010-07-273417","volume":"117","author":"CA Dinarello","year":"2011","unstructured":"Dinarello CA (2011) Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117:3720\u20133732. https:\/\/doi.org\/10.1182\/blood-2010-07-273417","journal-title":"Blood"},{"key":"6040_CR207","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1056\/nejmoa0807865","volume":"360","author":"I Aksentijevich","year":"2009","unstructured":"Aksentijevich I, Masters SL, Ferguson PJ et al (2009) An autoinflammatory disease with deficiency of the interleukin-1\u2013receptor antagonist. N Engl J Med 360:2426\u20132437. https:\/\/doi.org\/10.1056\/nejmoa0807865","journal-title":"N Engl J Med"},{"key":"6040_CR208","doi-asserted-by":"publisher","first-page":"1276376","DOI":"10.3389\/fnagi.2023.1276376","volume":"5","author":"WM Pardridge","year":"2023","unstructured":"Pardridge WM (2023) Treatment of Parkinson\u2019s disease with biologics that penetrate the blood\u2013brain barrier via receptor-mediated transport. Front Aging Neurosci 5:1276376. https:\/\/doi.org\/10.3389\/fnagi.2023.1276376","journal-title":"Front Aging Neurosci"},{"key":"6040_CR209","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s12974-014-0212-5","volume":"11","author":"XF Meng","year":"2014","unstructured":"Meng XF, Tan L, Tan MS et al (2014) Inhibition of the NLRP3 inflammasome provides neuroprotection in rats following amygdala kindling-induced status epilepticus. J Neuroinflammation 11:212. https:\/\/doi.org\/10.1186\/s12974-014-0212-5","journal-title":"J Neuroinflammation"},{"key":"6040_CR210","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s12974-018-1236-z","volume":"15","author":"C Qiao","year":"2018","unstructured":"Qiao C, Zhang Q, Jiang Q et al (2018) Inhibition of the hepatic NLRP3 protects dopaminergic neurons via attenuating systemic inflammation in a MPTP\/p mouse model of Parkinson\u2019s disease. J Neuroinflammation 15:193. https:\/\/doi.org\/10.1186\/s12974-018-1236-z","journal-title":"J Neuroinflammation"},{"key":"6040_CR211","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s12916-026-04688-0","volume":"24","author":"L Lin","year":"2026","unstructured":"Lin L, Li Z, Su F et al (2026) An autonomous siRNA delivery system targeting NLRP3: implications in Parkinson\u2019s disease. BMC Med 24:166. https:\/\/doi.org\/10.1186\/s12916-026-04688-0","journal-title":"BMC Med"},{"key":"6040_CR212","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-018-06522-5","volume":"9","author":"C Xu","year":"2018","unstructured":"Xu C, Lu Z, Luo Y et al (2018) Targeting of NLRP3 inflammasome with gene editing for the amelioration of inflammatory diseases. Nat Commun 9:1\u201314. https:\/\/doi.org\/10.1038\/s41467-018-06522-5","journal-title":"Nat Commun"},{"key":"6040_CR213","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/sciadv.abe2888","volume":"7","author":"T Wan","year":"2021","unstructured":"Wan T, Pan Q, Ping Y (2021) Microneedle-assisted genome editing: a transdermal strategy of targeting NLRP3 by CRISPR-Cas9 for synergistic therapy of inflammatory skin disorders. Sci Adv 7:1\u201315. https:\/\/doi.org\/10.1126\/sciadv.abe2888","journal-title":"Sci Adv"},{"key":"6040_CR214","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/pcmedi\/pbab014","volume":"4","author":"W Liu","year":"2021","unstructured":"Liu W, Li L, Jiang J et al (2021) Applications and challenges of CRISPR-Cas gene-editing to disease treatment in clinics. Precis Clin Med 4:179\u2013191. https:\/\/doi.org\/10.1093\/pcmedi\/pbab014","journal-title":"Precis Clin Med"},{"key":"6040_CR215","unstructured":"NCT06822517 (2025) US National Library of Medicine. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT06822517. Accessed 8 Jan 2026"},{"key":"6040_CR216","unstructured":"VENT-02 (2026) Ventus Therapeutics. https:\/\/www.ventustx.com\/pipeline\/nlrp3\/. Accessed 8 Jan 2026"},{"key":"6040_CR217","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1002\/mds.30307","volume":"40","author":"N Clarke","year":"2025","unstructured":"Clarke N, Thornton P, Reader V et al (2025) Anti-neuroinflammatory and anti-inflammatory effects of the NLRP3 inhibitor NT-0796 in subjects with Parkinson\u2019s disease. Mov Disord 40:2199\u20132208. https:\/\/doi.org\/10.1002\/mds.30307","journal-title":"Mov Disord"},{"key":"6040_CR218","unstructured":"NCT05924243 (2024) US National Library of Medicine. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05924243. Accessed 10 Jan 2026"},{"key":"6040_CR219","unstructured":"NCT06556173 (2025) US National Library of Medicine. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT06556173. Accessed 11 Jan 2026"},{"key":"6040_CR220","unstructured":"NCT07157735 (2026) US National Library of Medicine. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT07157735. Accessed 12 Jan 2026"},{"key":"6040_CR221","unstructured":"ISM8969 (2026) Press Releases. Insilico Medicine. https:\/\/insilico.com\/news\/az7xmeem81-insilico-medicine-receives-ind-approval. Accessed 12 Jan 2026"},{"key":"6040_CR222","doi-asserted-by":"publisher","first-page":"130184","DOI":"10.1016\/j.bmcl.2025.130184","volume":"122","author":"S Dorich","year":"2025","unstructured":"Dorich S, Auger A, Wang L et al (2025) Discovery of novel NLRP3 inhibitors enabled by a high-throughput screen. Bioorg Med Chem Lett 122:130184. https:\/\/doi.org\/10.1016\/j.bmcl.2025.130184","journal-title":"Bioorg Med Chem Lett"},{"key":"6040_CR223","doi-asserted-by":"publisher","first-page":"14897","DOI":"10.1021\/acs.jmedchem.3c01398","volume":"66","author":"D Harrison","year":"2023","unstructured":"Harrison D, Billinton A, Bock MG et al (2023) Discovery of clinical candidate NT-0796, a brain-penetrant and highly potent NLRP3 inflammasome inhibitor for neuroinflammatory disorders. J Med Chem 66:14897\u201314911. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c01398","journal-title":"J Med Chem"},{"key":"6040_CR224","unstructured":"VTX3232 (2024) Ventyx Biosciences. United States Securities and Exchange Commission. https:\/\/www.sec.gov\/Archives\/edgar\/data\/1851194\/000095017025029245\/vtyx-20241231.htm. Accessed 14 Jan 2026"},{"key":"6040_CR225","unstructured":"VTX3232 (2025) NLRP3 Inhibitor VTX3232 Well Tolerated, Improves Parkinson Symptoms in Phase 2a Trial. NeurologyLive. https:\/\/www.neurologylive.com\/view\/nrlp3-inhibitor-vtx3232-well-tolerated-improves-parkinson-symptoms-phase-2a-trial. Accessed 14 Jan 2026"},{"key":"6040_CR226","unstructured":"NCT02134964 (2015) US National Library of Medicine. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT02134964. Accessed 5 Jan 2026"},{"key":"6040_CR227","unstructured":"NCT01768975 (2014) US National Library of Medicine. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT01768975. Accessed 5 Jan 2026"},{"key":"6040_CR228","unstructured":"NCT03534297 (2020) US National Library of Medicine. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT03534297. Accessed 5 Jan 2026"},{"key":"6040_CR229","unstructured":"OLT1177\u00ae Dapansutrile (2026) Trials. Olatec. https:\/\/www.olatec.com\/trials.html. Accessed 5 Jan 2026"},{"key":"6040_CR230","doi-asserted-by":"publisher","first-page":"149129","DOI":"10.1016\/j.brainres.2024.149129","volume":"1842","author":"A Chatterjee","year":"2024","unstructured":"Chatterjee A, Mohapatra J, Sharma M et al (2024) A novel selective NLRP3 inhibitor shows disease-modifying potential in animal models of Parkinson\u2019s disease. Brain Res 1842:149129. https:\/\/doi.org\/10.1016\/j.brainres.2024.149129","journal-title":"Brain Res"},{"key":"6040_CR231","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1002\/cpdd.1162","volume":"12","author":"DV Parmar","year":"2023","unstructured":"Parmar DV, Kansagra KA, Momin T et al (2023) Safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral NLRP3 inflammasome inhibitor ZYIL1: first-in-human phase 1 studies (single ascending dose and multiple ascending dose). Clin Pharmacol Drug Dev 12:202\u2013211. https:\/\/doi.org\/10.1002\/cpdd.1162","journal-title":"Clin Pharmacol Drug Dev"},{"key":"6040_CR232","unstructured":"NCT04731324 (2021) US National Library of Medicine. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT04731324. Accessed 16 Jan 2026"},{"key":"6040_CR233","unstructured":"NCT04972188 (2021) US National Library of Medicine. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT04972188. Accessed 16 Jan 2026"},{"key":"6040_CR234","unstructured":"NCT05186051 (2022) US National Library of Medicine. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05186051. Accessed 16 Jan 2026"},{"key":"6040_CR235","unstructured":"NCT06398808US (2024) National Library of Medicine. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT06398808. Accessed 16 Jan 2026"},{"key":"6040_CR236","unstructured":"NCT05981040 (2024) US National Library of Medicine. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05981040. Accessed 16 Jan 2026"},{"key":"6040_CR237","unstructured":"ZYIL1 (2023) FDA favors Phase 2 trial of oral ZYIL1 in Parkinson\u2019s patients. Parkinson's News Today. https:\/\/parkinsonsnewstoday.com\/news\/fda-oks-phase-2-clinical-trial-oral-zyil1-parkinsons\/. Accessed 16 Jan 2026"},{"key":"6040_CR238","unstructured":"NCT04086602US (2020) National Library of Medicine. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT04086602. Accessed 17 Jan 2026"},{"key":"6040_CR239","unstructured":"RO7486967 (2022) BP43098 A Study to Assess the Safety of RO7486967 in Patients with COPD. NHS Health Research Authority. https:\/\/www.hra.nhs.uk\/planning-and-improving-research\/application-summaries\/research-summaries\/bp43098-a-study-to-assess-the-safety-of-ro7486967-in-patients-with-copd-2\/. Accessed 17 Jan 2026"},{"key":"6040_CR240","unstructured":"ISRCTN16847938 (2022) A study to evaluate the safety, tolerability, processing by the body and mechanism of action of RO7486967 in participants with ulcerative colitis. ISRCTN The UK\u2019s Clinical Study Registry. https:\/\/www.isrctn.com\/ISRCTN16847938. Accessed 17 Jan 2026"},{"key":"6040_CR241","doi-asserted-by":"publisher","first-page":"e1471","DOI":"10.1002\/ctm2.1471","volume":"13","author":"B Klughammer","year":"2023","unstructured":"Klughammer B, Piali L, Nica A et al (2023) A randomized, double-blind phase 1b study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of the NLRP3 inhibitor selnoflast in patients with moderate to severe active ulcerative colitis. Clin Transl Med 13:e1471. https:\/\/doi.org\/10.1002\/ctm2.1471","journal-title":"Clin Transl Med"},{"key":"6040_CR242","doi-asserted-by":"publisher","first-page":"7261","DOI":"10.1021\/acs.jmedchem.1c00599","volume":"64","author":"B Oronsky","year":"2021","unstructured":"Oronsky B, Guo X, Wang X et al (2021) Discovery of RRx-001, a Myc and CD47 downregulating small molecule with tumor targeted cytotoxicity and healthy tissue cytoprotective properties in clinical development. J Med Chem 64:7261\u20137271. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c00599","journal-title":"J Med Chem"},{"key":"6040_CR243","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s40265-023-01838-z","volume":"83","author":"N Jayabalan","year":"2023","unstructured":"Jayabalan N, Oronsky B, Cabrales P et al (2023) A review of RRx-001: a late-stage multi-indication inhibitor of NLRP3 activation and chronic inflammation. Drugs 83:389\u2013402. https:\/\/doi.org\/10.1007\/s40265-023-01838-z","journal-title":"Drugs"},{"key":"6040_CR244","unstructured":"Nibrozetone (RRx-001) (2026) EpicentRx. https:\/\/www.epicentrx.com\/product-pipeline\/. Accessed 17 Jan 2026"},{"key":"6040_CR245","unstructured":"Gordon R, Bhatt K, Jayabalan N et al (2024) Validating the clinical stage NLRP3 inflammasome inhibitor nibrozetone as a disease-modifying therapeutic for Parkinson's disease [abstract]. Mov Disord. 39(suppl 1). https:\/\/www.mdsabstracts.org\/abstract\/validating-the-clinical-stage-nlrp3-inflammasome-inhibitor-nibrozetone-as-a-disease-modifying-therapeutic-for-parkinsons-disease\/. Accessed 18 Jan 2026"},{"key":"6040_CR246","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.psyneuen.2007.09.004","volume":"32","author":"I Goshen","year":"2007","unstructured":"Goshen I, Kreisel T, Ounallah-Saad H et al (2007) A dual role for interleukin-1 in hippocampal-dependent memory processes. Psychoneuroendocrinology 32:1106\u20131115. https:\/\/doi.org\/10.1016\/j.psyneuen.2007.09.004","journal-title":"Psychoneuroendocrinology"},{"key":"6040_CR247","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.4103\/1673-5374.371344","volume":"18","author":"L Bellingacci","year":"2023","unstructured":"Bellingacci L, Canonichesi J, Mancini A et al (2023) Cytokines, synaptic plasticity and network dynamics: a matter of balance. Neural Regen Res 18:2569\u20132572. https:\/\/doi.org\/10.4103\/1673-5374.371344","journal-title":"Neural Regen Res"},{"key":"6040_CR248","doi-asserted-by":"publisher","unstructured":"Yang F, Qin Y, Wang Y, Meng S et al (2019)\u00a0Metformin Inhibits the NLRP3 Inflammasome via AMPK\/mTOR-dependent Effects in Diabetic Cardiomyopathy.\u00a0Int J Biol Sci\u00a015:1010\u20131019. https:\/\/doi.org\/10.7150\/ijbs.29680","DOI":"10.7150\/ijbs.29680"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-026-06040-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-026-06040-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-026-06040-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T14:42:14Z","timestamp":1784212934000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-026-06040-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":248,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["6040"],"URL":"https:\/\/doi.org\/10.1007\/s12035-026-06040-2","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"23 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.\u00a0","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Generative artificial intelligence tools, including ChatGPT 5.2 and Gemini 3, were used solely to support language editing and improve clarity of expression in selected portions of this manuscript. All conceptual content, scientific interpretations, analyses, and conclusions are the original work of the authors. The authors have critically reviewed, revised, and approved the final version of the manuscript and assume full responsibility for its content.","order":4,"name":"Ethics","label":"GenAI Disclosure Statement","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"774"}}